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Introduction:   Hemangiomas are the most common benign tumor of infancy.1   They are 
unique in that their behavioral course is well-described with a microvascular proliferative 
phase, quiescent phase and regressive fatty involuting phase.2-4  First, it is posited in this 
work that the cell of origin will have angiogenic and adipogenic properties, like the 
pericyte.5  Second, the predilection of the lesion to areas of embryologic fusions in the head 
and neck6-9 indicate that the neural crest may be involved.  Previous research focused on the 
angiogenic characteristics of proliferating hemangiomas, this work is novel in that it 
investigates markers involved in adipogenesis.  This study explores the possibility that 
hemangiomas are pericyte-like stem cell tumors, derived from the neural crest, capable of 
adipocyte differentiation. 
 
Methods:  Markers for pericytes, stem cells and neural crest c lls as well as adipocyte 
differentiation were analyzed using using immunohistochemistry, immunofluorescence 
and quantitative RT-PCR.  These markers included:  NG2, SMA, calponin, CD90(Thy1), 
GLUT1, dlk (pericytes); Pauf5 (Oct4), Nanog, Sox2, Sox9, Sox10, c-myc (stem cells); 
Nestin, Sox10, NGFR (p75), NG2 (neural crest cells) and C/EBPα, C/EBPβ, C/EBPδ, 
PPARγ, dlk, RXR, SREBF, Sox9, and Krϋppel-like factors (KLF2, KLF4, KLF5, KLF6, 
KLF15) (adipocyte differentiation markers).  Immunohistochemistry and 
immunofluorescence was done on formalin-fixed, paraffin-embedded archival tissue.  
qRT-PCR was performed on 15 hemangioma specimens (5 proliferating, 3 early 
quiescent, 4 late quiescent, and 5 involuting) and compared to Human Dermal 
Microvascular Endothlial Cells (HDMEC) utilizing the ∆∆Ct method of analysis.  
Hemangioma phase was determined by clinical notes.  To compare hemangioma phases, 
a one-way ANOVA was done with a Tukey HSD post hoc analysis. 
 
Results:  Immunohistochemistry identified these markers in the periluminal structures 
within the hemangiomas:  GLUT1, dlk, SMA, and Nestin.  Immunofluorescence 
identified these markers in a confirmatory pattern: GLUT1, dlk, SMA, Nestin, Sox2, 
Calponin and NG2.  The qRTPCR analysis revealed that the relative expression of all 
(pericyte, stem cell, neural crest and adipocyte diff rentiation) analyzed markers was 
greater than that of the HDMEC control.  Significant differences were found between the 
hemangioma phases for Sox9, C/EBPβ and KLF2 
 
Conclusion:  The work presented in this thesis is novel and informative.  It demonstrated 
that hemangiomas indeed express pericyte, stem cell and neural crest cell markers.  This 
is the first study to identify factors involved in adipocyte differentiation including dlk, 
PPARγ and KLFs.  The complex adipogenesis transcription cascade complicates the 
ability to draw conclusion in regard to adipocyte differentiation.  However, the data 
presented provides support for the theory that hemangiomas are pericyte-like stem cell 
tumors derived from the neural crest capable of adipocyte differentiation 
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Hemangiomas are the most common benign tumor of infancy1 and yet optimal 
treatment and their pathogenesis remain unknown.  They are unique among tumors in that 
their behavioral course is well-described with a proliferative, quiescent and involuting 
phase.2-4  However, the different phases progress with extremely variable times of 
duration from patient to patient.  In general, the lesion appears within the first days to 
weeks of birth as a pale, blue-ish patch.3  This patch, although not always observed, 
transforms into a red-pink papule of microvascular components which proliferate and 
grow disproportionately compared to the infant’s growth, Figure 1a.   
Hemangiomas vary from vascular malformations in that ey are present at birth 
and grow proportionately with the child.  On histology, diagnosis can be made with a 
high degree of confidence on the basis of strong immunoreactivity with antibodies 
against the glucose transporter protein isoform 1 (GLUT1).10-13  This can assist in the 
differentiation between normal vasculature of the skin, vascular malformations, and other 
benign vascular tumors (pygonic granuloma, tufted angioma and kaposiform 
hemangiomendothelioma).13 
Most (~80%) of lesions have a benign course8, 14 but common complications 
during the proliferative phase include ulceration, bleeding and pain.15, 16  Depending on 
the location and size of the lesion, visual development and airway can be 
compromised.16-18  The proliferative phase lasts arguably from 2 weeks to 1 year.  To 
date, there is no way to predict how long a lesion will grow, how large a lesion will 
become or the complications that may ensue..   
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Here is an example of a common (a) proliferating/early quiescent hemangioma in an 
infant.  The lesion is bright red and well-circumcised, no ulceration or functional 
impairment resulted from the clinical course.  The next panel (b) shows the same patient 
with the lesion in the late quiescent/involuting phase one year later.  The fibrofatty 
residuum can be seen characterized by a change in th color from red to a skin-colored 
tone as well as a decrease in the size. 
 
After the proliferative phase, the lesion enters a quiescent phase.  During this 
phase, little change is seen within the clinical milieu of the lesion.  There is no further 
growth or change in color and the incidence of complications related to bleeding or 
function are, again, related to location and size.  The quiescent phase is variable in 
duration, lasting from weeks to years.  The final phase is the involuting phase.  The lesion 
begins to shrink and the color regresses from the red-pink vascular color to a skin-tone or 
scar appropriate to the patient, Figure 1b.7, 19-21  Some lesions will completely regress and 
leave no visible residuum while others will be left wi h a fibrofatty scar.22  It is 
(a)    (b) 
 3 
 
commonly quoted that 30% of lesions will involute by age 3, 50% by age 5 and 80% by 
age 8.22, 23 
Obvious outliers exist in the patient population but overall, most hemangiomas 
present and progress in the outlined manner.  Other distinctive characteristics of 
hemangiomas are in whom and where they present.   Hemangiomas occur more 
commonly in female infants15, 16, 24-28 of Caucasian and white-Hispanic descent.26, 27  
They are also more common in premature infants.8, 28, 29  The distribution of lesions is 
predominantly in the head and neck region, though lesions occur throughout the body.6-9  
For a full review of the literature concerning epidemiology of hemangiomas see 
Supplement Text. 
Each of these unique elements have lent to physician speculation on the origin of 
hemangiomas.  Most previous research and treatments focu  on the proliferative elements 
including vascular endothelial cells and factors influencing angiogenesis and 
vasculogenesis such as basic fibroblast growth factor (bFGF), vascular endothelial 
growth factor (VEGF) and matrix metallopeptidase-9 (MMP-9).  Given the relation of the 
lesion’s appearance to labor and delivery, there is conjecture surrounding changing 
estrogen levels and hypoxic events including the influe ce of hypoxia-induced factor-1α 
(HIF-1α).  Hypothesises posited include: a viral etiology, placental emboli material, 
endothelial progenitor cells, genetic abnormalities, developmental field defects as well as 
angiogenic, hormonal, and hypoxia-induced growth factors.  For a full review of the 
literature regarding these hypotheses and growth factors see Supplement Text. 
Current medical treatments target angiogenesis and include certain chemotherapy 
agents (interferon α, cyclophsophamide and vincristine) as well as corti s eroids.  
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Propranolol, recently introduced, displays a remarkable ability to shrink proliferative 
lesions, although the exact mechanism of action is still unknown.  Nonetheless, medical 
treatments can be inadequate for complicated lesions leading to indications for surgical 
excision and use of laser treatments.  For a full review of the treatment modalities see 
Supplement Text. 
SPECIFIC AIMS 
Taking the unique behavioral and clinical characteris ics together, we formulated 
an alternative hypothesis to those already in practice.  The theory investigated in this 
work is that hemangiomas are pericyte-like stem cell tumors, derived from the neural 
crest, capable of adipocyte differentiation.  This w ll be accomplished using 
immunohistochemistry, immunofluorscence and qRT-PCR to identify related cell 
markers.  The implications of this hypothesis may create better prognostic markers and 
new therapeutic targets such as proadipogenic factors.  A summary of the hypothesis is 
illustrated in Figure 2. 
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Figure 2:  Overview of Hypothesis.   
(a) Cranial neural crest cells differentiate into the tsame cells in the head and neck 
region as mesenchymal stem cells do elsewhere, includi g pericytes and vascular 
smooth muscle cells. 
(b) Pericytes play an active role in (1) primitive formation of blood vessels during 
vasculogenesis, (2) organized angiogenesis and (3) adipogenesis in established 
adipocyte tissue. 
(c) Proliferating hemangiomas involve formation of unorganized microvascular 
components which during the involuting phase organize into mature blood vessels 
accompanied by fibrofatty tissue development.  Adapted from Kahn Science 
2008.42  CREDIT: P. HUEY    
 
Adipogenesis Vasculogenesis Angiogenesis 
Neural Crest Stem Cell  Mesenchymal Stem Cell  
Embryologic Stem C ell  
 







Aim 1:  Demonstrate hemangiomas bear lineage markers of pericyt s 
Neural glial protein 2 (NG2), smooth muscle actin (SMA), calponin, 
CD90 (Thy-1), GLUT1 and Delta-like kinase (dlk, aka Pref-1) 
Given the microvascular and the fatty component of hemangioma progression, our theory 
posits that hemangiomas originate from a cell entity capable of differentiating into both 
microvascular and fatty cell types.   
.  Pericytes are perivascular cells surrounding microvessels such as arterioles, 
capillaries, and venules.30-33  They play an active part in developmental and regulation of 
angiogenic processes.34  Similar to multipotent mesenchymal stem cells, pericytes have 
been shown to differentiate into chondrocytes, osteocytes, and adipocytes.35, 36  The 
pericyte has stem cell-like properties because it is capable of differentiation into 
microvascular components during vasculogenesis and angiogenesis and adipocytes.  A 
landmark study by Tang et al. provides reasonable evidence that, in mice, the pericyte is 
the precursor cell within adipocyte tissue that forms new adipocyte cells.5, 37 
Pericytes have been isolated from skeletal muscle, pancreas, adipose tissue, brain 
and placenta using CD146, PDGFR-β, and NG2 expression in the absence of 
hematopoietic, endothelial, and myogenic markers.38, 39  Juvenile pericytes are reported to 
express smooth muscle cell markers such as calponin and SMA as well as NG2 in the 
absence of mature smooth muscle cell marker such as SM22-α and SMMHC.40 GLUT1 
and dlk are also markers demonstrated in pericytes.39, 41  To date, there is no known 






Aim 2:  Demonstrate hemangiomas bear lineage markers of stem cells 
Pauf5 (Oct4), Nanog, Sox2, Sox9, Sox10, c-myc 
If indeed hemangiomas originate from a pluripotent cell type, they should demonstrate 
stem cell markers.  Previous work identified mesenchymal stem cells in hemangioma 
tissue which were at the highest concentration during the proliferative phase.43  These 
cells have the potential for clonal proliferation as well as for multi-lineage differentiation 
including adipocyte, osteoblast, chondrocyte, myocyte, neuronal cell and hepatocyte.44, 45  
Additionally, these hemangioma cells were more similar to stem cells than endothelial 
cells as the isolated cells express surface markers SH2(CD105), SH3, SH4, CD90 (Thy-
1), CD29, SMA, VEGFR-1/Flt-1, neurolipin, and CD133 but not hematopoietic markers: 
CD45 and CD14 or endothelial markers: CD34 and CD31.43, 45  CD90 (Thy-1) a 
mesenchymal stem cell marker, was the gene most differentially up-regulated in 
proliferating compared with involuting phase hemangiomas in a micro-array analysis.46 
Isolated hemangioma cells when injected subcutaneously in the back of 
immunodeficient mice organized into functional GLUT1+ and CD31+ vessels within 14 
days of implantation.13, 47  Two months after implantation the vessels diminished and 
human adipocytes became evident.  Furthermore, GFP-labeled hemangioma stem cells in 
vivo were shown to form adipocytes in addition to the endothelial lining of the vessels 
indicating that the implanted cells were not murine-derivied.47  This supports the concept 
that there is innate programming in the hemangioma stem cell for both its proliferative 
and involutive characteristics. 
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When analyzing hemangioma endothelial cells, the diff rentiated cells exhibit an 
expression profile and behavior much closer to that of fetal endothelial cells compared to 
adult endothelial cells.  This suggests that hemangioma cells are not fully differentiated 
or they maintain a degree of pluripotency.47-52 
A host of stem cell markers exist in an elegant and complicated regulatory 
transcription cascade for a differentiation pathway yet to be completely understood.  This 
study includes a small subset of these markers: Sox2, Nanog, Pauf5 (Oct4), Sox9, NGFR 
(p75), NG2, and Nestin.  Previous work by this labor t ry analyzed these markers: c-
myc, Sox2, Nanog, Pauf5, Nestin, NG2, Sox10 and CD90(Thy-1).  Each of these markers 
had a qRT-PCR relative expression greater than the control endothelial cells.  Markers 
were included based on their potential overlap in other cell types, such as pericytes and 
neural crest cells, as well as biologic processes, such as adipogenesis. 
Aim 3:  Demonstrate hemangiomas bear lineage markers of neural crest cells 
Nestin, Sox10, NGFR (neurotrophin factor receptor aka p75), NG2 
Most hemangiomas occur in the head and neck.  This leads to the postulation that 
hemangiomas are derived from a cell-line found predominantly in the head and neck, 
such as neural crest cells.  Not only are neural crest cells found predominately in the head 
and neck, but they are also considered to be a stem cell line.  Of interest, multiple lines of 
cells (pericytes, adipocytes, myocytes and osteoblasts) that are thought to be of 
mesoderm origin appear to be derived from the neural crest in the head and neck 
region.53-55  Specifically of importance in hemangiomas, head an  neck blood vessel 
pericytes and smooth muscle cells are derived from the neural crest.56 
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In addition to most lesions being located in the craniofacial region, there appears 
to be a pattern in regards to the location within te head and neck.  Waner et al., when 
reviewing hemangioma distribution in the head and neck region, observed that lesions 
appear in defined regions such as the sites of embryonic fusion.6  The distribution 
observed is demonstrated in Figure 3.  Interestingly, these are sites of neural crest cell 
migration which follow a predictable and non-random pathway with precise targets in the 
head and brachial arches.57 
Figure 3: Distribution of hemangiomas in the head and neck region 
Waner et al. presented a review of the 
distribution of hemangiomas in the head and 
neck region.  The focal sites of hemangioma 
occurrence are superimposed on the 
embryological fusion plates.6 
 
Failure of proper neural crest migration 
leads to significant morphological abnormalities of the face, neck and cardiovascular 
system.58, 59  The constellation of symptoms associated with PHACE syndrome (posterior 
fossa anomalies, hemangioma, arterial lesions, cardiac abnormalities/aortic coarctation, 
and abnormalities of the eye60) are proven to be caused by neural crest defects, with the 
exception of hemangiomas.  The hemangioma involved in PHACE syndrome is typically 
larger, termed “segmental” hemangiomas.  An example of the distribution of this larger 
hemangioma subtype is illustrated in Figure 4.  By association, hemangiomas may also 
be a result from a neural crest defect. 
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Figure 4: Segmental hemangioma distribution 
 
Haggstrom et al. analyzed the characteristics of large 
segmental hemangiomas.61  This is the pattern of 
distribution found.  As shown, the segmental 
hemangiomas tend to follow the distribution of the 
trigeminal nerve, indicating that there are neural 
derivatives involved in the origin of hemangiomas.  
The “beard distribution” is similar to the Segment 3. 
• Segment 1 (frontotemporal) 
• Segment 2 (maxillary) 
• Segment 3 (mandibular) 
• Segment 4 (frontonasal) 
 
Nestin, NGFR, and Sox10 are markers for neural crest-st m cells.62, 63  Nestin, an 
intermediate filament expressed in neuroepithelial stem cells is often expressed in multi-
lineage progenitor cells.62  NGFR is associated with cell differentiation to glial and neural 
cells possibly explaining distribution of large hemangiomas, termed segmental 
hemangiomas, along the branches of the trigeminal nerve.  Sox10 interacts with Pax3 to 
activate Mitf expression.  This is a well-associated motif with the ventral neural crest 
mirgration as well as denominating cells destined for the head and neck.64, 65  Previous 
work by this lab identified Nestin, Sox10 and NG2 in hemangioma tissue via qRT-PCR 






Aim 4:  Demonstrate hemangiomas express adipocyte differentiatio  markers 
CCAAT-enhancer-binding protein(C/EBP)α, C/EBPβ, C/EBPδ, 
peroxisome proliferator-activated receptors (PPAR)γ, Delta-like kinase 
(dlk aka Pref1), retinoid x receptor (RXR), sterol regulatory element-
binding transcription factor 1 (SREBF), Sox9, Krϋppel-like factors (KLFs) 
It is interesting to question how a vascular lesion with microvascular proliferative 
behavior stops growing and subsequently regresses into a fibrofatty scar.  This suggests a 
maturation pathway that converts the lesion into adipocyte-like tissue.  Less time and 
energy has been spent on this peculiar behavior.  If indeed, the cell of origin of 
hemangiomas is a pericyte-like or rather a preadipocyte-like cell then hemangiomas 
should demonstrate markers of adipocyte differentiation. 
To date, the exact details of the adipogenic differentiation transcription cascade 
remains to be completely understood; however, it is understood that differentiation 
involves a number of temporally regulated gene-exprssion events including known 
transcription factors, chromatin remodeling, feedback loops, and a number of inhibitory 
factors.  The most well-known and studied transcription factors are the delta-like kinase 
(dlk, aka Pref-1), peroxisome proliferator-activated r ceptors (PPARs) and the CCAAT-
enhancer-binding proteins (C/EBPs).  More recently, the Krϋppel-like Factors (KLFs) 
have been implicated in the regulatory cascade of adipogenesis.   
Dlk is the major inhibitory molecule of adipogenesis in concert with Sox9.  As 
dlk and Sox9 levels decrease, C/EBPβ and δ rise transiently followed by the expression 
of PPARγ within a positive feedback loop with C/EBPα.  These temporally expressed 
factors ensure commitment and transcription of adipocyte-specific genes that contribute 
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to the necessary machinery for mature adipocyte functio .  Certain KLFs positively 
(KLF4, KLF5, KLF6, and KLF 15) and negatively (KLF2) regulate the aforementioned 
proteins.  These are the transcription factors that will be of focus in this work.  A 
summary is offered in Figure 5, but for a more detail d review of adipogenesis and KLFs 
see Supplement Text. 
 
Figure 5:  Complex transcriptional cascade for adipocyte differentiation.   
Summary image of transcriptional cascade involved in adipocyte differentiation beginning with preadipocytes/pericytes and ending 
with a mature adipocyte.  Adipocyte specific genes i clude those proteins necessary for sequestration, pr duction and modification of 
lipid and lipid byproducts.   If hemangiomas have a default adipocyte differentiation target, they should express adipocyte 
























Immunohistochemical analyses were performed using formalin-fixed, paraffin-
embedded archival tissue.  Staining was performed on 5µm sections.  The sections were 
deparaffinized with xylene for 20 minutes and rehydrated through graded ethanol 
solutions.  To quench endogenous peroxidases, the slides were incubated with 3% H²O², 
dual endogenous enzyme block (S2003, Dako, Tokyo, Japan), for 5 minutes.  Antibody-
binding epitopes were retrieved using target retrieval solution (S1699, Dako, Tokyo, 
Japan) (citrate buffer, pH 6).  Then, the sections were incubated with GLUT1, SMA, dlk, 
nestin, desmin, PDGFR-β, and p75 NGFR at dilution of 1:500, see Table 2 for details.  
For detection, the sections were incubated for 10 minutes for the two steps in the labeled 
streptovidin-biotin2 system, (K0675, Dako, Tokyo, Japan).  The final step consisted of 
Liquid DAB+ Substrate Chromagen System (K3468, Dako, Tokyo, Japan) for 10 minutes 
followed by counterstaining with hematoxylin. 
Solutions 
Dual endogenous enzyme block (S2003, Dako, Tokyo, Japan 
Target retrieval solution (10x) (S1699, Dako, Tokyo, Japan) 
Labeled streptavidin-biotin2 system, horseradish peroxidase (LSAB2)  
(K0675, Dako, Tokyo, Japan) 
• Biotin labeled affinity isolated goat anti-rabbit and goat anti-mouse 




• Streptavidin conjugated to horseradish peroxidase in PBS containing stabilizing 
protein and anti-microbial agents 
Liquid DAB+ Substrate Chromagen System (K3468, Dako, Tokyo, Japan) 
• 3,3’-diaminobenzidine in chromage solution 
• Imidazole-HCl buffer, pH 7.5, containing hydrogen peroxidase and an anti-
microbial agent 
Immunofluorescence Staining 
Paraffin embedded tissue samples were sampled for protein markers using 
immunofluorescence analysis on unstained 5µm sections using species-specific 
antibodies. All antibodies were diluted to a 1:100 concentration in 1%BSA/PBS 
according to manufacturer recommendations.  Species appropriate IgG-Alexa-Fluor 488 
and 568nm, dilution  1:500, (Molecular Probes, Eugene, OR) secondary antibodies, with 
subsequent 4',6-diamidino-2-phenylindole (DAPI) nuclear counterstaining were used.   
Tissues were viewed with a Zeiss Axiovert 200M Fluorescence/Live cell Imaging 
Microscope (Carl Zeiss Imaging Solutions, Thornwood, NY). Digital images were 
acquired using the Zeiss LSM510 confocal computer system (Carl Zeiss Imaging 
Solutions, Thornwood, NY). 
 The sections were deparaffinized with xylene for 20 minutes and rehydrated 
through graded ethanol solutions.  Antigen retrieval utilized heat mediated method with 
the slide covered by 10mM citrate buffer at 95°C for 20 minutes.  Slides were cooled to 
room temperature for 20 minutes.  They were washed with PBS-tween20 for 5 minutes, 
twice.  Serum blocking utilized normal goat serum blocking solution for 15 to 30 
minutes, no wash required only removal of excess.  Slides were incubated overnight with 
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the primary antibody with a 1:100 dilution (diluted in 1% BSA in PBS; OR in Sigma 
Antibody Diluent).  Slides were then washed in PBS-tween20 for 5 minutes, twice and 
followed with incubation with the secondary antibody, fluorophore labeled, for 30 minute 
with a 1:500 dilution of appropriate fluorophore labeled secondary antibody to the 
matching primary animal, such asRabbit-anti-rat IgG (488, 568nm), H+L Ab (Invitrogen 
10039) in PBS (no BSA added).  After which, slides were washed in PBS-tween20 for 5 
minutes, three times.  Finally, DAPI cover slip solution was applied to slides and slides 
were visualized under fluorescence microscope. 
Solutions 
Citrate Buffer (10mM Citric Acid, 0.05% Tween 20, pH 6.0) 
Citric acid (anhydrous), 1.92 g 
Distilled water, 1000 ml 
Adjust pH to 6.0 with 1N NaOH and then add 0.5 ml of Tween 20 and mix well. Store 
this solution at room temperature for 3 months or at 4 C for longer storage. 
Normal Goat Serum Blocking Solution 
5% goat serum (blocking) 
1%BSA (stabilizer) 
0.05% Tween 20 (detergent and surface tension reducer) 
In 1X PBS, pH 7.2 
Mix well and store at 4 ºC.   
Washing Solution (1X PBS, 0.05% Tween 20, pH 7.2) 
500ml 1X PBS 




All samples were collected in accordance with an approved HIC protocol 
(#0507000430) as reviewed by the Yale University Medical School IRB.  As these 
samples were collected from children, fully informed parental consent and childhood 
assent, when age appropriate, were obtained prior to surgery.  Only the tissue remaining 
following collection of the pathological specimen was used for this experiment.  
Specimens for RNA extraction were separated into groups based on their clinical history, 
presentation at the time of excision and pathology report as described below:  
• Proliferative: lesions with interval growth between the last two clinical visits 
preceding surgery.   
• Early quiescent:  lesions demonstrating no interval growth between the last two 
clinic visits preceding surgery and less than 1.5 years of age.   
• Late quiescent:  lesions demonstrating no interval growth between the last clinic 
visits preceding surgery and greater than 1.5 years of age.   
• Involuted:  demonstrated interval regression between th  last two clinic visits 
preceding surgery and were at least 3 years of age. 
For comparison to normal microvascular endothelial cells, human dermal microvascular 
endothelial cells (HDMEC) were used as the comparative controls. 
Hemangioma tissue samples obtained at the time of excision were immediately 
minced with straight razors into 1mm pieces and placed in 10mL Qiagen®RNA Later 






All implements were washed and treated with a RNAse way(Molecular 
BioProducts)  wash and baked at 200°C to eradicate RNAse enzymes.  Isolation was 
completed on ice. 
Using Manufacturer RNAzol®RT Protocol 
RNA extraction was done according to RNAzol®RT manuf cture protocol.  
Briefly, tissue was immediately disrupted using a mortor and pestle and placed in chilled 
RNAzol®RT.  Cell cultures were lysed in the culture dish by removing culture medium, 
adding RNAzol®RT and passed through a pipette to ensure full lysis.  Water was added 
and the samples were incubated at room temperature (15–25°C) for 15 minutes.  Following 
centrifugation at 12,000 g for 15 min, DNA, proteins and most polysaccharides form a 
semisolid pellot with the RNA in the supernatant. 
To precipitate the RNA, the RNA supernatant was transferred to a new tube and 
equal parts of isopropranol were added to each sample.  Samples were incubated at room 
temperature for 10 minutes and centrifuged at 12,000 g for 10 minutes.  The supernatant 
was carefully removed and the remaining RNA pellet was washed twice with 75% 
ethanol and centrifuged at 4,000 - 8,000 g for 3 minutes.  Without drying, the RNA pellet 
was dissolved in water to approach the RNA concentration of 1-2ug/mL.  Total RNA 
concentration and purity were analyzed by nanodrop spectrophotometry.  Samples were 
stored at -80°C until analysis. 
Using Manufacturer QIAGEN® miRNeasy Mini Protocol 
RNA from frozen tissue or culture samples was also obtained according to Qiaqen 
miRNesay Mini protocol.  Briefly, for frozen tissue samples, QIAzol Lysis 
 19 
 
Reagent®(Qiagen) was added directly to tissue and smples were homogenized using 
TissueRuptor®(Qiagen).  For cell culture, cells were trypsinized with 0.25% Trypsin 
(1X) (Gibco: 15050-065) and cells were pelleted.  To disrupt the cells, QIAzol Lysis 
Reagent was added to the pellet followed by QIAshredder homogenizer (Qiagen). 
The disrupted and homogenized samples were incubated at room temperature for 
5 minutes.   Chloroform was added to the samples and vortexed for 15 seconds.  The 
samples were incubated at room temperature for 3 minutes followed by centrifugation for 
15 minutes at 12,000 x g at 4°C.  After centrifugation, the sample separated into 3 phases: 
an upper, colorless, aqueous phase containing RNA; a white interphase; and a lower, red, 
organic phase.  The upper aqueous phase was transferred to a new tube and 1.5 volumes 
of 100% ethanol was added to the new tube.   
To isolate the RNA, the solution and any precipitate was pipetted onto an RNeasy 
Mini spin column in a 2 ml collection tube.  The spin column was centrifugated at ≥8000 
x g (≥10,000 rpm) for 15 seconds at room temperature.   The flow-through was discarded.  
Any remaining solution was placed onto the spin column and centrifugated.  To wash the 
column, Buffer RWT was added to the column and centrifugated for 15 seconds at ≥8000 
x g (≥10,000 rpm).  The flow-through was discarded.  Next, two separate Buffer RPE 
washes were performed with centrifugation for 15 seconds at ≥8000 x g (≥10,000 rpm) to 
wash the column.  The flow-through was discarded.  The column was dried by 
centrifuging the spin column for 2 minutes at ≥8000 x g (≥10,000 rpm).  The spin column 
was placed on a new 1.5 ml collection tube.  Finally, 50 µl RNase-free water was pipetted 
directly onto the RNeasy Mini spin column membrane d the spin column was 
centrifugated for 1 minute at ≥8000 x g (≥10,000 rpm) to elute the RNA. 
 20 
 
Quantitative Real Time Polymerase Chain Reaction 
One-step Taqman-based quantitative RT-PCR was performed using TaqMan® 
RNA to-CT™ 1-Step Kit (Applied Biosystems, Foster City, CA).  RNA was extracted 
from the samples as described above.  RNA volume equivalent to 20ng was included as 
the template for the qRT-PCR reactions.  Reactions included Taqman® RT-PCR Mix 
(2x)(Applied Biosystems), Taqman® RT Enzyme Mix (40x)(Applied Biosystems, 
Foster, City, CA),  and Taqman® Gene Expression Assay (20x)(Applied Biosystems, 
Foster City, CA) as recommended by the manufacturer.  Gene expression assays using 
ABI Taqman primers (Applied Biosystems, Foster City, CA), previously validated by the 
manufacturer, were completed to quantify gene expression, see Table 1 for complete list.  
All reactions were run in triplicate.  Reactions that did not contain any RNA template 
were included as negative controls. Reactions were processed on an Applied Biosystems 
7900HT Sequence Detection System.  
The run method used the following conditions: 
Standard mode 
Reverse transcription       48C for 15 minutes 
Activation of AmpliTaq Gold® DNA polymerase, Ultra Pure 95C for 10 minutes 
Cycle 40x Denature     95C for 15 seconds 
Anneal/Extend    60C for 1 minute 
Amplification data was analyzed with the ABI Prism SDS 2.1 software (Applied 
Biosystems).  Relative quantification of gene expression was performed by the ∆∆Ct 
method.  GAPDH expression served as the endogenous control to normalize expression 
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within each sample measurement.  HDMEC, endothelial cells, were used for the 
comparative relative expression. 
Statistical Analysis 
Hemangioma phases, proliferative, early quiescent, late quiescent and involuted, 
were compared with the three endothelial controls using a one-way ANOVA, p<0.05, 
followed by a post hoc Tukey HSD to identify any omnibus F value obtained.  Analyses 
were done using SPSS.  Relative expression (∆∆Ct) is expressed via a log2 scale and thus 
traditional standard deviation calculations are not sufficient.  The upper and lower error 
bounds are not linear.  To calculate upper error this formula was used: UE=2^-((∆∆Ct) - 
SD of ∆∆Ct)).  To calculate the lower error this formula was used: LE=SD of ∆∆Ct –(2^-
(∆∆Ct)) 
 
Summary of Methods 
Performed by Student:  
• Immunohistochemistry staining 
• Specimen Collection 
• RNA extraction  
• qRT-PCR 
• Statistical Analysis 
 
Performed as Services:  





The H&E staining shows a high density of cells within a multinodular formation 
with microvessels formed throughout the nodule.  Red blood cells can be seen within the 
microvessels.  The GLUT1 staining is positive but limited to the perivascular cells and 
the red blood cells serve as an internal control as they also stain positive.  Similar to 
GLUT1, dlk positively stained the perivascular cells.  SMA positively stains more 
extensively throughout the perivascular areas.  Nestin stains the perivascular cells 
positively throughout the hemangioma tissue and is seen weakly throughout the nodules.  
Desmin, PDGFRβ and NGFR did not stain the hemangioma tissue.  See Table 2 and 
Figures 6 and 7. 
Figure 6: Positive immunohistochemistry staining 
Each of the panels shows positive staining.  In the higher magnification images (40x) it is 
clear that the positive staining is seen in the perivascular cells: (a) shows GLUT1 staining 
which is positive and limited to the perivascular cells, (b) shows dlk, which shows similar 
staining to GLUT1, limited to the perivascular cells, (c) SMA stains the perivascular cells 
but goes beyond the immediate periluminal cells and (d) Nestin also stains the 
perivascular cells but also shows positive staining weakly throughout the tissue. 
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Figure 7: Negative immunohistochemistry staining 
In contrast to the previous Figure 6, each of these antibodies (a) desmin, (b) PDGFR-β 






























Indiret immunofluoresence showed GLUT1 staining the cells lining the 
microvessels as well as weakly throughout the hemangioma tissue.  CD31, an endothelial 
cell marker, positively stained the cells lining the microvasculature of the lesion.  Sox2, a 
nuclear stem cell marker, stains the nuclei of the cells throughout the hemangioma.  
Nestin, a stem cell and neural crest marker, stains he perivascular cells.  Figure #    SMA 
and calponin, pericyte markers, stains the perivascul r ells of the microvessels.  NG2, a 
pericyte and neural crest marker, is weakly positive hroughout the tissue.  See Table 2 
and Figure 8 and 9.  PDGFRβ, NGFR and Sox10 did not stain the hemangioma tissue, 
Figure 10. 
 
Figure 8: Positive immunofluorescence staining: stem cell and neural crest markers 
Shown are the results of indirect immunofluorscence on formalin fixed paraffin-
embedded tissue (color-coded to match the fluorophore).  DAPI staining visualizes the 
nuclei; (a) shows GLUT1, the diagnostic marker for hemangiomas, staining the cells 
lining the capillaries as well as weakly throughout the tissue; (b) shows CD31, an 
endothelial cell marker, lining the microvasculature of the lesion; (c) shows Sox2, a stem 
cell marker, staining and (d) is the corresponding merged image with DAPI; (e) 
demonstrates positive Nestin staining, a neural crest marker. 
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Figure 8: Positive immunofluorescence 



















Figure 9: Positive immunofluorescence staining: pericyte markers 
Shown are the results of indirect immunofluorescence on formalin fixed paraffin-
embedded tissue (color-coded to match the fluorophore).  DAPI staining visualizes the 
nuclei; (a) shows positive staining for SMA in the periluminal regions; (b) indicates that 
dlk is more diffusely positive but with increased con entration in the periluminal regions; 
(c) demonstrates intense calponin staining around the luminal borders; (d) shows weakly 











Figure 10: Negative 
immunofluorescence staining 
Each of these antibodies (a) NGFR, (b) 
PDGFR-β and (c) Sox10 did not stain the 
hemangioma tissue.  The basement 
membrane of the epidermis is a positive 
control for Sox10.  The negative staining 
of NGFR and PDGFR-β is consistent with 
the immunohistochemistry staining seen in 
Figure 7. 
Samples 
RNA was extracted from 15 samples and included in the s udy.  The mean age of 
the child at the time of excision for the proliferative group (n=5), early quiescent group 
(n=3), late quiescent group (n=4) and involuted group (n=3) phase was 255±113 days, 







Table 3: Descriptive statistics for hemangioma samples 
Age at Time of Excision (days) 
Hemangioma Phase N 
Mean Std. Deviation 
Proliferative 5 255 113 
Early Quiescent 3 161 51 
Late Quiescent 4 1141 550 
Involuted 3 2014 1471 
All Phases 15 824 959 
 
Quantitative Real Time – Polymerase Chain Reaction 
Descriptive statistics for the mean relative expression of each of the probes to 
HDMEC cells are presented in Table 4.   All of the gene expression analyzed had a mean 
relative expression greater than the HDMEC control, Figure 11.  Each of the gene 
expression analyzed compared using a oneway ANOVA at α = 0.05 revealed a 
significant difference among the hemangioma phases.  There were three significant 
differences found: Sox9 (F 3,7 = 28.760, p<0.000), C/EBPβ (F 3,7 = 4.776, p = 0.041), 
and KLF2 (F 3,9 = 4.064, p = 0.044), Table 5.  No other significant differences were 
found.  A post hoc Tukey’s HSD was used to identify the source of the significant 
omnibus F for Sox9, C/EBPβ and KLF2, Table 6 and Figure 12.  It indicated that e 
relative expression of Sox9 was significantly greater in the involuted phase compared to 
the proliferative, early quiescent and late quiescent phases.  Also, the relative expression 
of C/EBPβ was significantly greater in the proliferative phase compared to the early 
quiescent phase.  Finally, the relative expression of KLF2 was significantly less in the 




Figure 11: Hemangioma relative expression of mRNA markers  
qRT-PCR mean relative expression (2^(-∆∆Ct)) ± upper and lower error bounds for mRNA targets in hemangioma  samples (n=15) 
calibrated to endothelial control (HDMEC) expression.  GAPDH expression to normalize.  Graphed on a log rithmic scale. 















































































































































































Figure 12: Hemangioma phases relative expression ofmRNA markers  
qRT-PCR mean relative expression (2^(-∆∆Ct)) ± upper and lower error bounds for mRNA targets for hemangioma phases.   
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DISCUSSION 
 Hemangiomas clearly express stem cell, neural crest and pericyte markers.  The 
immunohistochemistry and immunoflourescent data allows for visualization of markers 
in the histopathology structure.  GLUT1 is the diagnostic marker of hemangiomas.  The 
cells that stain positively for GLUT1 are the periluminal cells which make these cells of 
interest in regards to investigating the origin of the hemangioma.  Specific pericyte 
markers, SMA, dlk and calponin, stain the same areas as GLUT1 indicating that the 
hemangioma cell is likely a pericyte-like cell.  Although, desmin and PDGFRβ did not 
stain positive.  These markers typically indicate mature pericytes and it is not surprising 
that hemangioma cells do not express these markers. 
Nestin, a stem cell and neural crest marker, stains similar perivascular cells as 
GLUT1 indicating that the hemangioma cell type may h ve a neural crest and stem cell 
derivative.  NG2 is a pericyte and a neural crest marker and interestingly stains weakly 
throughout the tissue indicating that the hemangioma tissue may be derived from a neural 
crest cell.  Similarily, Sox2, a stem cell marker, stains diffusely throughout the 
hemangioma tissue.  The specific staining of the hemangioma perivascular cells with 
stem cell, neural crest and pericyte markers supports the theory posited in this work.  
Diffuse stem cell markers throughout the tissue support that hemangioma cells are 
capable of pluripotent differentiation. 
The qRT-PCR data also supports expression of stem cell (Sox2, Pauf5, Nanog, 
Sox9), neural crest (NGFR) and pericyte (dlk) markers in hemangiomas.  Each of these 
mRNAs were expressed at least a 10-fold expression greater than the control endothelial 
cells.  Previous data collected by this lab via FACS analysis showed that hemangioma 
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cells were more like pericytes than endothelial cells as they expressed CD90(Thy1) and 
NG2, Figure 14. 
Figure 14: Fluorescence Activated Cell Sorting (FACS) analysis 
As shown here, previous work done by this laboratory revealed through a FACS analysis 





Each of the adipocyte differentiation factors investigated had a relative expression 
greater than the endothelial cells.  The RXR and SREB receptors had the lowest relative 
expression compared to the endothelial cells and was more consistently expressed at that 
low level throughout the hemangioma phases.  Dlk and Sox9 demonstrated the most 
increase in fold expression compared to endothelial cells.  Not surprising that their levels 
mirrored each other as dlk is an influencing factor on Sox9 expression.  Dlk is the major 
inhibitory molecule for adipogenesis and Sox9 directly binds to the promoters of C/EBPβ 
and C/EBPδ, early pro-angiogenic factors.  Late differentiation factors, C/EBPα and 
PPARγ, also displayed a relative expression greater than endothelial cells.  The KLFs 
investigated all had relative expression greater than endothelial cells.  KLF2, an 
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inhibitory factor, had the greatest relative expression while KLF15, a proadipogenic 
factor, had the least relative expression.   
 Unfortunately, only three significant differences were found between the 
hemangioma phases.  Sox9 was found to be greater in the voluted phase when 
compared to each of the other phases.  This may indicate that adipogenesis is an ongoing 
process during hemangioma growth and proliferation and in fact the angiogenic growth is 
accompanied by adipogenesis.  The involuted phases may actually represent either fully 
differentiated epidermal and soft tissue cells or potentially the hemangioma cells have 
undergone apoptosis, subsequently leaving normal tissue behind.  Scarring that is often 
observed after a hemangioma has involuted may be a consequence of increased 
inflammatory molecules in the area of the hemangioma. 
 C/EBPβ was expressed greater in the proliferative phase compared to the early 
quiescent phase.  This factor is expressed early in adipocyte differentiation.  Again, 
proliferating hemangiomas may actually represent a bal nce between angiogenic and 
adipogenic differentiation.  It is possible that as lesions begin to slow in growth during 
the quiescent phase and adipocyte differentiation begins to phase into the terminal 
differentiation phases. 
 Finally, KLF2, an inhibitor of adipogenesis, was significantly greater during the 
late quiescent phase compared to the proliferative phase.  This follows the theory that 
pluripotent differentiation occurs during the early proliferative phases and as the lesion 
matures, the cells either fully differentiate into their end product or possibly they undergo 
apoptosis.  KLF2 being less expressed in the proliferative phases would allow for early 
adipocyte differentiation.  KLF2 being higher express d in the late quiescent phase 
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indicates that the cells are less likely to undergo adipocyte differentiation or that the 
KLF2 is able to slow or even regress the adipocyte diff rentiation.  KLF2 inhibits 
adipocyte differentiation via inhibition of PPARγ expression.  PPARγ is the positive 
regulator for adipocyte differentiation and is required for mature adipocytes to be 
maintained.  If KLF2 is increased older lesions, it is possible to question if KLF2 can stop 
adipocyte maturation, can cause regression of adipocytes to a less mature state or even 
apoptosis of the affected cells.  Many questions remain about the influences of the 
adipocyte differentiation transcription cascade on hemangioma development and 
progression. 
The limitations of this study must be acknowledged.  Gene expression profiling 
gathered through qRT-PCR in animal and human specimens are subject to scrutiny based 
on the extreme variability of gene expression and transient nature of many proteins i  
vivo.  Hemangiomas are no exception.  The lesions are a small microenvironment in the 
host patient and any analysis of hemangioma tissue repr sents ongoing and concurrent 
processes within the lesion as well as variability among patient.  Moreover, the 
heterogeneity of hemangiomas has always been clinically apparent.  The qRT-PCR data 
further capitulates the variability among these lesion  as demonstrated by the wide upper 
and lower errors for the relative expressions. 
The sample size and the phase criteria can also be criticized.  The statistical power 
of the study is limited by the small sample size (n=15) and the complex comparisons 
needed.  In the literature, many authors use the age of the child as the defining factors 
between proliferative and involuting lesions.  In order to best determine “like” lesions we 
relied heavily on two individual surgeon’s notes in order to delineate proliferative, 
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quiescent and involuting lesions.  We believe that clinical appearance is more important 
to the underlying pathology and microenvironment compared to the quantitative age of 
the child at time of excision.  Counter intuitively, the early quiescent lesions were 
younger on average than the proliferative lesions; however, there was no significant 
differences between the mean ages between the two groups (t-test, p=0.23).  Age 
continues to be important; however, clinical observation appears to be more consistent 
with mRNA expression profiles. 
Furthermore, the data presented is based on the ∆∆Ct method of calculation for 
relative expression compared to endothelial cells.  Endothelial cells were chosen as the 
comparative sample because aberrant endothelial cells remain a well-accepted source for 
the cell of origin for hemangiomas.  To strengthen this study, relative expression 
compared to adipocytes would increase the ability to identify the similarities, if any exist, 
between hemangioma cells and adipocytes.  Additionally, using a standard curve would 
provide a stronger quantitative analysis for comparison between control samples and 
among hemangioma phases.   
Although definitive conclusions are difficult to draw based on the discussed 
limitations of qRT-PCR, including the small sample size of the study and variability 
among the patients, it is clear that the qualitative relative expression compared to 
endothelial cells exists for the markers examined.  The comparison between the 
hemangioma phases is a pioneering attempt to better qualify the characteristics of 
quiescent lesions.  Once a lesion has stopped growing, answering the parents’ question: 
“how long will this lesion be on my child?” is difficult to do.   
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Hemangioma pathophysiology is likely more complicated than originally 
anticipated with multiple processes (including adipogenesis, angiogensis and possibly 
apoptosis) occurring in a concert of balanced control shifts.  Research on the quiescent 
and involutive phases of hemangiomas may identify molecular markers that can be used 
for treatment targets or prognostic screening. 
 A number of observations, although not statistically significant, are worthy of 
discussion.  It appears that the overall quantity sem cell and neural crest markers 
decrease over time.  It might be inferred that as the lesions mature their pluripotent ability 
decreases along with the stem cell markers.  Also, one would expect a fibrofatty tissue to 
exhibit PPARγ, a marker of mature adipocytes.  In fact, the PPARγ expression was the 
lowest, though not significant in the involuted lesions.  Remembering that involuted 
lesions are either normal tissue or a fibrofatty scar, the low level of PPARγ goes along 
with the idea that tissue can revert to normal tissue.  The fibrofatty scar may in fact be the 
result of inflammation from the proliferative process that leaves scar tissue in the place of 
the hemangioma. 
 In regard to the KLFs, it is difficult to extrapolate a pattern.  One can state that 
KLFs are indeed expressed in hemangiomas but at this ime it is too intricate to infer the 
exact mechanism of control they have on hemangioma proliferation and involution.  
Likely the control that KLFs have on hemangioma progression is complex and involves 




Future studies are needed to investigate a number of areas left unexplained.  This 
thesis represents a work in progress and additional experiments await completion.  A list 
of partially complete and anticipated experiments is below. 
• Confirm expression of mRNAs examined by qPCR with western blot  
• Culture hemangioma cells and pericyte cultures (complete) 
o Treat with thiazolidinediones (TZD) 
 PPARγ agonist, promotes adipocyte differentiation 
 Preliminary work with Red-O staining indicates fat production 
within hemanigioma and pericyte cells 
 Possibly a novel treatment option for quiescent lesions 
o Silence dlk with a shRNA lentivirus vector 
 Dlk is the main inhibitor of adipocyte differentiation 
 Show that dlk is an inhibitor of hemangioma involution 
 Preliminary data indicates explants are capable of transfection, 
allowing for hemangioma macrostructure to remain intact 
• Animal study 
o Explant proliferating hemangioma into nude mouse 
o Treat with TZD 
• Identify single nucleotide polymorphisms at the dlkgene locus 




The work presented in this thesis is novel and informative.  It demonstrated that 
hemangiomas indeed express a number of stem cell, neural crest and pericyte markers.  
This is the first study to identify factors involved in adipocyte differentiation including 
dlk, PPARγ and KLFs.  The data presented provides support for the hypothesis that 
hemangiomas are pericyte-like stem cell tumors derived from the neural crest capable of 
adipocyte differentiation.  Further work will be needed to definitively identify the cell of 




Clinical Features of Hemangiomas 
Hemangiomas are the most common benign tumor in the pediatric population 
with an overall incidence estimate of 4 to 5%1 although earlier studies estimated 9 to 
13%.16, 20, 24, 25  Prior studies observed a marked female preponderac  compared to males 
at a ratio of 3:1,15, 16, 24-28 a predilection for light skin types,27, 67 and a higher incidence 
among premature infants, especially those weighing less than 1,500g.8, 28, 29  Lesions are 
seen predominantly in the head and neck region with a nonrandom distribution.6-9   
Hemangiomas are a well-studied tumor from a clinical st ndpoint.  The lesion 
typically appears within weeks of the infant’s birth but is not present at the time of birth.  
Grossly, an erythematous patch or a telangiectasia may be seen within hours to days of 
birth which then develops into an elevated red to purple lesion.3  The lesion is primarily 
composed of microvascular components in which angiogenesis is initially excessive, 
termed the proliferative phase, for approximately 1 year after birth.  Microscopically, the 
proliferative phase is identified by endothelial proliferation and hyperplasia with and 
without lumin formation in a multilobular pattern.2-4   Other cell types involved include 
mast cells, macrophages, plasma cells and pericytes.68  This is followed by the involuting 
phase consisting of a slow but inevitable regression of the disorganized vessels.  Mature 
blood vessels form with multi-laminated basement membranes.  These mature blood 
vessels are found among predominately adipocytes and co nective tissue, termed a 
fibrofatty residuum.7, 20, 21, 69  See Figure 1 for typical presentation. 
Traditionally described, involution occurs at approximately 10% per year, with 
50% of lesions involuting by 5 years of age, 70% by 7, and 90% by 9.70  Complete 
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involution of the lesion often occurs, leaving no clini al evidence of the hemangioma; 
however, nearly half of affected children will retain fibrofatty tissue or have scar 
formation at the site of the lesion.22, 23 
Diagnosis is made with a high degree of confidence on the basis of strong 
immunoreactivity with antibodies against the glucose transporter protein isoform 1 
(GLUT1).10-13  This assists in the differentiation between normal vasculature of the skin, 
vascular malformations, and other benign vascular tmors (pygonic granuloma, tufted 
angioma and kaposiform hemangiomendothelioma) which are not GLUT1 positive.13 
Most (~80%) hemangiomas are solitary in their presentation and create little 
concern due to their benign course.8, 71  For these lesions, “watchful waiting” is an 
appropriate conservative approach to treatment when siz , location, and behavior are 
unlikely to result in functional impairment or deformity.  Unfortunately, 10 to 20% of 
infants will suffer a complication secondary to thelesion and require treatment.68  The 
most common complication is ulceration which occurs in approximately 5% of affected 
children.15  Ulceration is associated with pain and blood lossand, in severe cases, 
necrosis can lead to loss of soft tissue including nose, ear and lip structures.15, 16  Infants 
can suffer from poor feeding and sleeping resulting in failure to thrive and even death 
from infection.15, 16 
Additional complications occur secondary to size and location.  For example, a 
hemangioma in the periorbital region blocking a child’s visual field or compressing the 
globe can lead to visual development impairment, astigmatism, amblyopia, exposure 
keratopathy, proptosis, and ptosis.16, 17, 72-74Another situation, involves lesions near the 
ear which can obstruct the external auditory canal d result in chronic/intermittent otitis 
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or decrease auditory conduction which can eventually lead to delayed speech 
development. 16, 75-77 
The location of lesions can indicate further underlying pathology.  Over half of 
children with lesions in the “beard” distribution (preauricular areas, the chin, anterior 
portion of the neck, and lower lip), shown in Figure 4 , have associated lesions in the 
orapharyngeal or subglottic region which can cause symptomatic airway obstruction 
requiring tracheostomy.16, 18  Furthermore, lumbrosacral lesions can be associated with 
underlying tethered spinal cord, urogenital and anorectal anomalies and these infants 
should be evaluated for such anomalies.78  
Also, the number of lesions can signify further underlying pathology.  Multifocal 
presentation or “disseminated hemangiomatosis” defines an infant with greater than 5 
cutaneous hemangiomas, typically 1 to 10mm in diameter.71, 79  Infants are at a higher 
risk of visceral hemangiomas and should be evaluated for lesions involving the liver, 
brain, gastrointestinal and lung. 80-82  These patients are also at risk for high-output 
cardiac failure,83, 84 gastrointestinal bleeding, hydrocephalus and consumption 
coagulopathy (aka Kasabach-Merrit syndrome).81, 82, 85 
Of diagnostic and clinical importance is a subgroup f atients with large (>5cm), 
often termed “segmental,” hemangiomas, an example is shown in Figure 4.  These 
hemangiomas are  associated with structural anomalies of the brain, cerebral vasculature, 
eyes, aorta, and chest wall.  This is known as the neurocutaneous disorder called PHACE 
syndrome (OMIM 606519).86  The PHACE acronym refers to posterior fossa anomalies, 
hemangioma, arterial lesions, cardiac abnormalities/aortic coarctation, and abnormalities 
of the eye.60 
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Treatment Modalities and Mechanisms for Hemangiomas 
Many treatments target associated symptoms such as antibiotics for infection, 
anti-inflammatories, narcotics for pain and barrier agents for friction prevention.  These 
modalities do little in regards to hastening the involution of hemangiomas.  The known 
pharmacologic agents that quicken hemangioma involution are corticosteroids, 
chemotherapy agents (examples: interferon α, vincristine and cyclophosphamide) and 
propranolol.  Physicians often utilize these drugs as well as laser and surgery to improve 
the symptoms and outcomes for the affected children.  However, each of these treatments 
is associated with an adverse side effect profile as discussed below. 
Cryotherapy 
Although not used widely in the United States, cryotherapy use is indicated 
particularly for superficial and peduculated hemangiomas and is used more often in 
Europe and South America.16, 87-89  Use of this therapy is criticized because the risk of 
hypopigmentation and atrophic scar formation exists.16, 87, 89 
Corticoidsteroids 
Zarem and Edgerton reported, in 1967, a case series of patients with 
hemangiomas that responded to prednisolone90 and from that point in time corticosteroids 
became the mainstay treatment for problematic hemangiomas.  Oral corticosteroid 
therapy continues to be effective in stopping the growth of hemangiomas but the response 
is variable.91, 92  Potential adverse effects include cushingoid featur s, growth retardation, 
gastroesophageal reflux, ulceration, hypertension, hyperglycemia, glycosuria, behavioral 
disturbances, and immunosuppression; yet upon cessation of the drug these side effects 
all regress.93-96  The recommended dosage is 2-5 mg/kg/day methprednisolo e or 
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prednisone for 3 to 4 weeks with a gradual taper.15, 16  If no response is noted within 8 to 
10 days, the treatment should be stopped and alterntive therapies should be employed.89  
The effectiveness of corticosteroids is noted only i  actively proliferating lesions and 
involuting lesions should be treated with other therapies.23 
Intralesional steroid injections, typically 3-5 mg/k  triamcinolone,15, 16, 92 are used 
for the treatment of problematic subglottic and periorbital lesions and their use is noted 
particularly in the otolaryngology literature.97-100  Concern in regards to periorbital lesion 
injections exists because central retinal artery occlusion, ophthalmic artery occlusion and 
retinal embolization can occur.101-104  Proponents for this treatment believe that with the 
correct dose and delivery complications can be avoided.105, 106 
Although the exact mechanism remains unknown for how steroids inhibit 
proliferating hemangiomas, it likely involves inhibit on of angiogenesis.  Steroids exert 
their effect by binding directly with steroid receptors.  The steroid-receptor complex is 
then capable of binding to the gene DNA at a glucocorticoid response element (GRE) 
which modulates promoter activity.  This interaction leads to direct altered gene 
expression of between 10 and 100 genes which is cell-typ  and environment dependent.   
The effects of steroids on hemangiomas are likely rlated to pro-angiogenic 
factors.  Hasan et al. found that in a hemangioma injected with intralesional steroids that 
these factors were decreased: platelet-derived growth factor-A  and –B (pro-angiogenic); 
interleukin-6 (pro-inflamatory, smooth muscle); transforming growth factor-b1 and -b3 
(pro-apoptotic), while these factors remained unchaged: basic fibroblast growth factor 
(pro-angiogenic) and vascular endothelial cell growth factor (pro-angiogenic).107  Likely 
it is the decrease in these factors that influences th  angiogenesis. 
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Furthermore, the same group found an up-regulation of mitochondrial cytochrome 
b (cyt b) in hemangioma tissue following steroid-inuced and natural involution.107, 108  
Cyt b is a component of the mitochondrial respiratory chain and the location of this gene 
in the mitochondrial DNA is close to sequences thatresemble GREs, the promoter 
sequences that bind steroid-receptor complexes.109  Elevated expression of cyt b was also 
observed in senescent human cells110 and involuting lactating gland following 
weaning.111  The postulation is that the increased oxygen metabolism inhibits 
proliferation. 
Chemotherapy Agents 
Chemotherapy agents are another tool in the physician’s armamentaria saved for 
problematic corticosteroid-resistant hemangiomas.  This review will focus on the past and 
present treatments used more universally although it s ould be noted that there are other 
treatment modalities in the literature.  Other modalities not discussed include intralesional 
bleomycin112 and topical imiquimod(Aldara; Graceway Pharmaceuticals, LLC, Bristol, 
TN).113-116 
Interferon-α 
Interferon-α (IFN-α) originally developed as an antiviral agent was subsequently 
discovered to have a range of activities including immunemodulting, anti-proliferative, 
and antiviral.117, 118  Anti-angiogenic and anti-tumor properties was unexpectedly found 
when treating patients with human immunodeficiency virus (HIV) infection with IFN-α 
and subsequently their Kaposi’s sarcoma, a vascular tumor associated with 
immunodeficiency, improved.118-122   
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IFN-α’s anti-angiogenic properties were first reported in 1980 by Brouty-Boye 
and Zetter that showed that IFN inhibited capillary endothelial cell migration in vitro.123  
Studies further supported the inhibitory action on endothelial migration and proliferation 
in vitro124 and in vivo.125  IFN-α may act indirectly by inhibiting pro-angiogenic stiumuli 
such as growth factors involved in collagen production and the proliferation of 
endothelial cells, smooth muscle cells, and fibroblasts.126 
IFN-α therapy was implemented in 1989 by White et al. and Orchard et al. to 
several severe cases by of hemangiomas with positive responses.127-129 After these initial 
cases, IFN-α become the second-line agent for corticosteroid-resistant hemangiomas.130 
Unfortunately, a case series reported spastic diplegia, a condition of hypertonia 
and spasticity in the muscles of the lower extremities, developing in 20% (5 out of 26) of 
children treated with IFN-α for hemangiomas.  Paralysis was permanent in 3 of 5 
children.131, 132  Due to the severe adverse effect, IFN-α dropped out of favor as the 
treatment of choice for corticosteroid-resistant hemangiomas. 
Vincristine 
Vincristine is a mitotic inhibitor that acts on tubulin dimmers and inhibits the 
assembly of microtubules structures.  The use of vincristine for the treatment of 
hemangiomas was prompted by Ghadially’s finding that identified high tubulin content in 
endothelial cells,133 a major blood vessel component.  Inhibition of tubulin in 
hemangioma-associated endothelial cells ceases the proliferation of the lesion.  The 
current dose is given intravenously on a weekly basis.  The dosage is 0.05mg/kg in 
children less than 10 kg or 1.5mg/m2 in infants greater than 10kg.95  Adverse side effects 
are dose-related and reversible and include gastrointest nal upset, constipation, fever, 
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headache, and peripheral and autonomic neuropathies.134  Vincristine has replaced IFN-α 
as the second-line agent in problematic corticosterid-resistant lesions because of the 
more benign side effect profile.134-137  This agent has been used for treating life-
threatening kaposiform hemangioendothelioma associated with Kasabach-Merritt 
syndrome.138-140 
Cyclophosphamide 
Cyclophosphamide is an alkylating agent introduced by Rush in 1966 to treat a 
giant cutaneous hemangioma that was resistant to the sclerosing agent sodium 
morhuate.141 Since this initial report, a handful of authors have published cases 
successfully using cyclophosphamide in patients with life-threatening hemangiomas.142-
147 
The proposed mechanism of cyclophosphamide in hemangiomas is that it blocks 
the proliferation of new capillaries resulting in shrinkage, fibrosis and subsequent 
regression of the tumor.  The published treatment dose is 10 mg/kg per dose for 3 or 4 
days intravenously or orally for 2 or 3 courses.142, 144, 146, 148  Consequent severe side 
effects include hematologic toxicity, hemorrhagic cystitis, avascular necrosis, 
cardiomyopathy, pulmonary fibrosis, gonadal damage and subsequent maliganacies.95, 149  
Proponents state the low-dose and limited administrat on decrease the risk of such 
adverse effects.95, 149 
Propranolol 
Propronolol is a non-selective β blocker and the most recent addition to the 
physician’s arsenal for treatment of hemangiomas.  It was discovered in 2008 as two 
children showed rapid regression of lesions while they were being treated for 
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cardiopulmonary conditions.150  A subsequent case series demonstrated excellent 
regression with no noted severe associated side effects.151  Other authors have also noted 
similar efficacy.152-156  The current recommended dose is 2 mg/kg/day.  Potential side 
effects of β-blockers include bradycardia, hypotension, hypoglycemia, rash, 
gastrointestinal discomfort/reflux, fatigue and bronchospasm.  Although the least 
dangerous of all the medical treatments at this time, patients are admitted for observation 
to receive their first doses to ensure they are stable on the medication.   
The mechanism of action for propranolol remains unknown.  One prospective 
explanation is vasoconstriction which decreases the blood flow to the lesion.  Propranolol 
was also found to reduce the pro-angiogenic factors: VEGF and bFGF and lead to 
increased apoptosis of capillary endothelial cells through the down regulation of the 
RAF-mitogen activated protein kinase pathway.150, 157  Another group found that this 
agent inhibits tubulogenesis and matrix metalloproteinase-9 (MMP-9).158 These 
observations create an argument for an anti-angiogen c property of propranolol. 
Laser 
The first reports of using a laser for treatment of vascular lesions were with argon 
lasers by Apfelberg et al. and Hobby, 1976 (488nm) and 1983 (514nm), respectively.159, 
160  The argon laser worked well for superficial port wine stains because of shallow 
penetration; however deeper, more involved lesions such as hemangiomas did not 
respond as well.161  Substantial risk of complications exist secondary to nonspecific 
damage to healthy epidermis and dermal tissue resulting in hypertrophic scaring, atrophic 




Laser therapy improved in the 1980’s based on the theory of selective 
photothermolyisis which stated that certain macrostructures could be selectively targeted 
for thermal destruction through specific radiant energy absorption.  Flash lamp-pumped 
pulse dye laser (575nm to 600nm) with surface cooling technology drastically improved 
outcomes by decreasing nontarget thermal damage by spacing out the exposure. 165-168 
The general premise of how lasers treat vascular lesions is (1) the laser radiant 
energy is emitted at a particular wavelength, (2) the energy is absorbed by a certain 
chromophore, in this case the target is oxyhemoglobin (585nm), and (3) subsequently that 
radiant energy is converted to thermal energy within e target.  By laser targeting 
hemoglobin, thermal damage occurs within the targeted blood vessels.  Ideally, minimal 
absorption occurs superficially in the epidermis and dermal layers.  However, melanin 
within the epidermis also absorbs the radiant energy which can result in damage and 
scarring and also limits the energy delivered to the underlying vessel pathology. 
Another laser currently used is called a neodymium-doped yttrium aluminum 
garnet laser (Nd:YAG) (1064nm) and it can be used alone.  It can also be converted to a 
frequency-doubled Nd:YAG where a Nd:YAG laser is pased through a potassium-titanyl 
phosphate crystal which halves the wavelength (doubling the frequency).169   For 
example, the wavelength is cut in half from the original 1064nm to 532nm.  This 
frequency-doubled Nd:YAG laser setup allows for longer and variable pulse duration 
with less complications and is effective for deeper netration of lesions 170, 171 and 
intralesional photocoagulation.172-174 Dynamic epidermal cooling is now standard with 
most laser treatments to decrease the nonspecific thermal damage to superficial and 




Surgery is typically reserved for those children with life or sensory-threatening 
lesions, though the threshold for the individual surgeon and family varies.  There is no 
consensus on which lesions require excision and which qualify for the “wait and watch” 
philosophy.  Much has been made of early psychological milestones.  One undeniable 
advantage of surgery is its rapid and definitive eff ct.179  Excision surgery can pose a risk 
of hemorrhage; however, with proper technique and operative planning, this can be 
avoided.  The other major complication among patients u dergoing excision surgery is 
related to anesthesia, which can be significantly riskier in younger children.  If surgery is 
indicated or opted, it is critical to ensure a pediatric care team. 
Hypothesis for Pathogenesis 
Hemangiomas are clinically well-studied pediatric tumors; however, very little is 
known about their origin.  Hemangiomas share the defining characteristic of endothelial 
proliferation which eventually turns into a fibrofatty residuum.  There is no clearly 
identifiable causal event associated with appearance of a hemangioma.  Observations 
have lead to proposed theories.  The following willdetail a number of theories posited 
including: viral, a placental embolic event, genetic mutations, endothelial progenitor 
cells, developmental field defects, the role of hypoxia, and angiogenesis factors. 
Viral 
A previous theory associated the link of Kaposi sarcoma, an endothelial cell 
tumor, to human herpes virus-8; however, this link was not found in hemangiomas.180  
However, another viral association discovered was th t recombinant avian leukosis 
viruses of subgroup J were isolated from field infected commercial layer chickens with 
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multiple surface and visceral hemangiomas.181  These hemangiomas were histologically 
similar to those present in humans. 
Aims at designing an endothelial tumor animal model found that the injection of 
mouse endothelioma cells known to have polyoma virus, a DNA tumor virus, which 
express middle T oncogene (PyMT, an early region gene), is capable of inducing 
hemangioma formation in adult and neonate species.182  Hemangioma rapid growth under 
these conditions was associated with cell recruitmen  rather than local proliferation.182, 183  
Almost 20 years later, direct transfection of a replication-competent avian splice 
retroviral vector with PyMT using the stem cell leuk mia (scl/tal-1) gene promoter and 
tva retroviral receptor resulted in lethal hemangioma development in vivo, similar to the 
prior study.184  Both these animal models provide an endothelial tumor model similar to 
the often lethal Kasabach-Merritt syndrome in humans.  These models and the associated 
avaian leukosis virus in chickens provide possible insight into more involved forms of 
hemangiomas but fail to provide substantial support in regards to the more common 
solitary benign lesions in human infants. 
Placental Embolic Material 
 Considerable support for a placental origin for the hemangioma exists.  
Observations found that the incidence of hemangiomas was higher among children of 
women who underwent chorionic villus sampling compared to children of women who 
did not undergo the procedure.185-187  The theorized mechanism is that placental injury 
and intravascular shedding of placental chorionic villi cells are capable of embolizing to 
receptive fetal tissues, especially to areas with hig blood flow such as the head and neck. 
188  After delivery, removal of the embolized cells from maternally secreted anti-
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angiogenic factors, like VEGF sequestering transmembrane receptor, sFlt-1, and the 
period of birthing hypoxia results in release of angiogenic factors such as VEGF. These 
events create a proangiogenic environment for the embolized placental cells.16, 189-192  
Proponents of this theory note that the unique self-limited growth of the hemangioma 
mirrors the life-cycle of placental endothelium.188, 193 
Furthermore, studies demonstrated a striking resemblance of hemangioma vessels 
and placental vessels including glucose transporter 1 (GLUT-1), merosin (α-2 laminin), 
Lewis Y, FcγRII (CD32), type III iodothyronine, indoleamine 2, 3 deoxygenase, and 
insulin-like growth factor 2 (IGF-2).11, 12, 46, 194-196  GLUT-1 is not expressed in normal 
skin microvasculature but it does stain positively in blood-barrier tissues including the 
placenta, erythrocytes, nerve endoneurium and perineurium.11  Merosin is only expressed 
in the placental chorionic villi, trophoblast, nervous system, eye, skeletal muscle and 
dermal-epidermal junctions.197-200  Lewis Y and FcyRII are found only in placental 
chorionic villi, perivascular macrophages and microglia.201  Also, a preferential gene 
expression profile between hemangioma tissue and placental tissue identified similar 
genes including 17-β hydroxysteroid dehydrogenase type 2 and tissue factor pathway 
inhibitor 2.193, 202 Interestingly, factors found to support placental growth have also been 
linked to hemangioma lesions and include epidermal growth factor (EGF), IGF1, IGF2 
and FGF4.46, 203-215  
Hemangiomas are likely not maternal placental derivatives.  Genetic 
investigations found that hemangiomas found no matern l microchimerism and identified 
only XY cells in lesions of male infants; therefore, indicating that the lesions are 
exclusively derived from the infant and therefore cannot be from the maternal placenta.51, 
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216, 217  However, the possibility that the origin is a cell r ated to the fetal trophoblast 
remains. 
The trophoblast, the functional unit of the placenta, is essentially a highly 
proliferative stem cell at the maternal-fetal junction.  The two main differentiated 
trophoblast roles are as 1) intermediate trophoblasts which establish the maternal-fetal 
circulation by eroding into the maternal spiral arteries and 2) syncytiotrophoblasts 
programmed to maintain and fuse with the syncytium, the maternal-fetal barrier.218  An 
embolized trophoblast, possibly “let loose” during a chorionic villous sampling 
procedure, could very well be either a trophoblast stem cell or a differentiated 
trophoblast. 
Tissue markers as noted above link hemangiomas to differentiated placental 
microvasculature not necessarily trophoblast stem clls.11  To date, no study has 
investigated specific trophoblast markers that may help determine the cell of origin for 
the hemangioma.  Syncytiotrophoblsts specific markers include Sox17 and GATA4219 
while intermediate trophoblasts are identified by double staining with cytokeritin 7 and 
HLA-G.220   
Syncytiotrophoblasts behave less like that of a hemangioma lesion. The nature of 
the intermediate trophoblast to orchestrate the microvascular formation of the maternal-
fetal circulation is more similar to the vascular proliferation of hemangiomas.  If the 
embolized cell is a differentiated trophoblast, it is likely an intermediate trophoblast and 
not a syncytiotrophoblast.  Human intermediate trophoblasts adopt a vascular phenotype 
as they differentiate.221   
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However, the behavior of the trophoblast is not only tightly regulated by a 
plethery of molecular pathways222 but critical vectorial relations exist.  Trophoblast stem 
cells in vitro quickly exit the mitotic cycle, differentiate and fuse to form a giant cell that 
degenerates in about 5 days.223 224-226  In order to overcome vectorial dependencies of 
trophoblast differentiation, explant methods were developed to preserve the relationship 
between the mesenchyme, basement membrane and the trop oblast epithelium. 227  
Explant models allow investigation of environment ad molecular pathways involved in 
regulation of placental growth and development.  Inerestingly, explanted hemangioma 
tissue into nude mice recapitulates a similar life-cycle behavior of the lesion i vivo.45  
This raises the question of how an embolized trophoblast, stem cell or differentiated, is 
able to structurally orchestrate and grow into a hemangioma, a complex microvascular 
lesion.  Further investigation is required before this heory can be accepted. 
Endothelial Progenitor Cells 
Endothelial progenitor stem cells which are capable of inducing postnatal 
formation of vascular tissue may be critical to hemangioma pathogenesis.47, 228  
Endothelial progenitor cells are stem cells capable of contributing to blood vessel 
formation.229  They are identified as expressing both CD34, an endothelial marker, and 
CD133, a stem cell marker.  These cells have been isolated from the bone marrow, blood 
circulation, fetal liver, and skeletal muscle.230, 231  They contribute to tissue 
vascularization during both embryonic and postnatal physiologic processes including 
vascular development, organ regeneration and tumor ne angiogenesis.232, 233  Endothelial 
progenitor cells express HIF-1α which promotes local production of VEGF, angiogenesis 
and mobilization of endothelial progenitor cells.234 
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Endothelial progenitor cells co-expressing CD34 andCD133 were identified in 
proliferating hemangiomas.235  These cells displayed unique cellular responses to 
angiogenic inhibitor endostatin.  The hemangioma endothelial cells had an angiogenic 
mRNA expression profiles more similar to umbilical ord blood-derived endothelial 
progenitor cells than to mature endothelial cells and.50, 52, 49  It is postulated that the 
proliferative activity is specific to immature endothelial cells and not specifically to 
hemangioma endothelial cells.236   
Children with hemangiomas demonstrated a 15-fold increase in peripheral 
circulation of endothelial progenitor cells at the ime of resection compared to age 
matched control children.237  The peripheral endothelial progenitor cells were cultured 
and stained positively for previously defined markers of hemangiomas: GLUT1, CD22 
and merosin.237   
Developmental Field Defects 
Developmental fields are parts of the embryo in which the development of 
complex structures are controlled and coordinated in a spatially ordered, temporally 
synchronizied and epimorphically hierarchial manner.238, 239  Disturbances in a field 
development may be corrected or they may lead to anom lies or incomplete 
differentiation.  These disturbances can occur at any point in the developmental process 
and result in different constellations of phenotype.  Early action can lead to extensive 
defects (e.g., cyclopic holoprosencephaly) while lat r ctions result in a lesser defects 
(e.g., cleft palate or postaxial polydactyly). Disturbances early may present with a 
malformation syndrome involving two or more fields (e.g. acrorenal, cardiomelic, 
gastromelic, or splenomelic anomalies).238, 239  If genetically caused, all structures 
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immediately involved consequently are genetically abnormal while those structures 
affected secondarily have normal genotypes. 238 
In regard to hemangiomas, specific interest in regard to developmental field 
defects lies in PHACE syndrome.  Posterior fossa malformations, arterial anomalies, 
cardiac and eye abnormalities are consistent with an early developmental field defect that 
occur at approximately 8 to 10 weeks of gestational age.240-242  The observation that 
hemangiomas also occur in these patients, especially large segmental hemangiomas, 
indicates that the underlying cause of hemangioma may be directed toward an early 
differentiation pathway. 
Genetic Disruptions 
Researchers found that hemangiomas are genetically derived from the child.  In 
conjunction with those studies, it was found that hemangioma cells displayed allelic loss.  
This loss of heterzygosity, seen in some cancers, may result in the loss of a tumor 
suppressor genes allowing for growth.243  Furthermore, analysis of in vitro and by direct 
tissue studies demonstrated clonality which means that hemangiomas may in fact arise 
from a single aberrant cell.50, 243 
Specific mutations have been identified; however, they are not consistently found 
in all hemangiomas studied.  Missense mutations in the genes encoding VEGFR2 (KDR), 
VEGFR3(FLT4) and TEM8 (ANTXR1) were identified.243, 244  These proteins are part of 
the complex which regulates the expression of VEGFR1.244  These germline missense 
mutations do not appear to cause systemic vascular abnormalities.  Germline mutations 
seen in identified genes are probably associated with a secondary somatic event, such as 
hypoxia, which triggers the expansion of endothelial cells within the lesion. These 
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findings do allow inferences to the importance of the affected genes and resulting 
proteins in the mechanism of pathology. 
Hypoxia 
The association of hemangiomas with premature infants d low birth weight 
infants has been demonstrated.28, 29, 245  Premature birth is also correlated with placental 
hypoxia and retinopathy of prematurity.246  Recently, studies have shown an association 
between hemangiomas and placental hypoxia247, 248 as well as retinopathy of 
prematurity.249 
These observations bring to light the possibility that hypoxia plays a role in the 
development of hemangioma.  Tissue hypoxia seems to be he most powerful inducer of 
angiogenesis.  Hypoxia-inducible factor-1α (HIF-1α ) is the main adaptive response to 
tissue hypoxia resulting in enhanced glucose uptake, increased red blood cells and the 
formation of new blood vessels.250  Not surprisingly, proper placental growth is tighly 
dependent on metabolism components such as oxygen, glucose, and pyruvate specifically 
through HIF-1α.250 
Hypoxia leads to the stabilization of HIF-1α and consequently to local production 
of downstream molecules: GLUT1, stromal cell-derived factors-1a (SDF-1a), VEGF and 
MMP.250-254  These factors are capable of initiating proliferation of endothelial cells.255-257  
It is thought that overexpression of GLUT1 receptor allows cells to scavenge glucose 
which provides energy for new vascularization as well as resist against apoptosis.254, 258 
HIF-1α was found at greater concentrations in proliferating hemangiomas when 
compared to involuting hemangiomas.253, 259  Herbert et al. found that hemangioma 
monocyte-derived endothelial-like cells in tissue clture displayed an increase of GLUT1 
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transcription and surface expression of GLUT1 protein after hypoxia treatment. 260  HIF-
1α and subsequent GLUT1 expression indicates that hypoxia may induce downstream 
molecules favorable for the proliferation of hemangiomas.  The cell culture study also 
indicates that this response is likely innate to the hemangioma cell. 
Serum concentrations of MMP-9 and VEGF were higher in proliferating 
hemangioma patients compared to involuted hemangioma patients, vascular 
malformations and control infants.261-263  Furthermore, the microenvironmental amount of 
VEGF, not the total concentration of VEGF, determined ormal or aberrant 
angiogenesis.264  This indicates that only one abnormal cell is needed for the necessary 
VEGF production to initiate hemangioma formation. 264 
Angiogenesis and Vasculogenesis 
Given the clinical characteristics of hemangioma, researchers anticipate the 
involvement of these two processes in the pathogenesis.  Angiogenesis is defined as the 
growth of new blood vessels from existing vasculature, while vasculogenesis involves de
novo development of vessels from prescursor cells in situ. Angiogenesis is orchestrated 
by a number of factors and environment cues.  Angiogenic factors include basic 
fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF).214, 265, 266  
One of the key environment cues for neovascularization is hypoxia which triggers the 
HIF-1α production.251  Vasculogenesis is considered to be an embryonic development 
process; however, recent evidence provides support for on going vasculogenic potential 
in the adult with the identification of endothelial progenitor cells. 
Angiogenic factors and receptors have been investigated in regards to 
pathogenesis, prognosis and treatment. Vasculogenesis of the lesion is not far fetched as a 
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number of potential precursor cell reservoirs exist including, dormant angioblasts,267 
placental trophoblasts, and bone marrow.268  Hemangioma tissue expresses a number of 
angiogenic markers and receptors including: bFGF, VEGF, MMP-9, estrogen receptors, 
SDF-1a and P1GF.214, 253, 265, 269-271  
Basic Fibroblast Growth Factor (bFGF) 
Basic fibroblast growth factor is a 146-amino acid polypeptide member of the 
heparin-binding growth factor family.266  In tissue culture, bFGF induces migration and 
proliferation of endothelial cells.272  bFGF was increased in urinary excretion in patients 
with vascular tumors;273 however, bFGF serum concentrations were similar among 
vascular tumor, vascular malformation and healthy control patients.211  bFGF mRNA was 
found predominantly in the tumor pericytes and endothelial cells indicating that bFGF 
may play a role in the angiogenesis of hemangiomas but it is likely not the critical 
molecule.211, 214 
Vascular Endothelial Growth Factor (VEGF) 
Vascular endothelial growth factor is a protein family consisting of with five 
splicing products, VEGF-A, -B, -C, -D and placenta growth factor.274  VEGFs mediate 
endothelial cell proliferation, migration, survival, cell-cell communication, differentiation 
and vessel permeability.275-279  VEGFs bind to three receptor tyrosine kinases:  VEGFR-1 
(Flt-1), VEGFR-2 (KDR/Flkt-1) and VEGR-3 (Flt-4).274  The critical role of VEGF-A, 
VEGFR-1, and VEGFR-2 in development of blood vessels was demonstrated in a study 
of knockout mice genetically engineered to be defici nt in the VEGFA and VEGFRs 
which died of abnormal vasculogenesis.275, 280 
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VEGF and VEGFRs are likely involved in the mechanism of hemangiomas; 
however, their exact role remains unclear.  VEGF serum concentrations are higher in 
patients with hemangiomas compared to patients with malformations and healthy 
controls.211  However, no difference in VEGF levels were found i  urine excretion 
between patients with vascular tumors compared to healt y patients.273  This makes 
urinary excretion of VEGF an unlikely candidate for sc eening or prognostic testing. 
Predictably, VEGF staining was greater in proliferating lesions compared to 
involuting lesions.214, 259, 281  Hemangiomas stained positively for a number of markers 
directly involved in the VEGF/VEGFR pathway.52, 235, 281  The majority of mRNA for 
VEGF was localized to pericytes and endothelial cells.211  VEGFR1 was reduced in 
hemangioma endothelial cells.244  Consequently, the low VEGFR1 expression resulted in 
VEGF-induced activation of VEGFR2 and downstream signaling pathways.244  
Correlative, serum levels of VEGFR1 were slightly lower in hemangioma patients 
compared to healthy controls and no trend was seen in serum levels of sVEGFR2.282  The 
localized manner of hemangiomas may not be sufficient to create a significant change in 
the serum levels of these soluble proteins. 
VEGF has a number of functions locally and distally.  Most hemangioma tissue 
cultures are endothelial cells or stem cells by nature; however, stromal cells also play a 
role in the mechanism of hemangioma.  These stromal cells express VEGF which act as 
an autocrine growth factor through the activation of VEGFR-2 as well as a paracrine 
factor for endothelial cell growth.283  VEGF can mobilize endothelial progenitor cells 
from the bone marrow to sites in need of neovascularization.284  Another VEGF function 
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is that it upregulates MMP-9 which is a factor also capable of mobilizing endothelial 
progenitor cells and for which there is a positive fe dback to VEGF.285   
Future treatment ideas may target this extremely angiogenic factor with antisense 
VEGF which was successful in hemangioma culture.286 
Estrogen 
Estrogen acts predominantly through estrogen receptors and is involved in a 
number of processes throughout the body including sexual development, fetal 
development, coagulation, and cardiovascular repair.  The level of circulating estradiol in 
the postnatal period is greater than later in life.253  In regard to hemangioma patients, the 
level of estrogen in patients with hemangiomas was significantly higher than that of 
healthy children.271  Furthermore, the serum level of estrogen and estrogen receptors in 
hemangioma tissue was greater in proliferating hemangioma patients when compared to 
involuting hemangioma patients.43, 287  This indicates that estrogen may play a role in the 
pathogenesis of hemangiomas. 
Estrogen may play a regulatory role in regards to key angiogenic factors involved 
in hemangiomas.  Expression of angiogencic growth factors (bFGF, IGF, TGFb) is 
induced by estrogen.16, 43, 288  Furthermore, VEGF, MMP-9 and SDF-1a expression are 
also all induced by estrogen.289-292  Estrogen itself can increase angiogenic activity, 
mobilize of endothelial progenitor cells and modulate vascular remodeling.293  A 
synergistic effect was found with VEGF and estrogen on the angiogenic potential of 
cultured  hemangioma endothelial cells.294  Estrogen is also protective for hypoxia-
induced apoptosis.295-297  Intriguingly, hemangioma cell cultures grew especially well in 
hypoxic environments supplemented with estrogen.253, 296, 298  These observations provide 
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support for the idea that estrogen may have a critical role in the pathogenesis of 
hemangiomas. 
 Treatment ideas for this regulatory molecule include antiestrogen and estrogen 
receptor antagonists.289 
Matrix Metallopeptidase-9 (MMP) 
Matrix metallopeptidase-9 (MMP), also known as collagenase IV, is an enzyme 
involved in the breakdown of extracellular matrix such as degrading type IV collagen and 
a number of other matrix proteins.299  The role of MMPs ranges from embryonic 
development to tissue remodeling.  MMP-9 is inducible n hypoxic environments after 
which and mRNA level and enzymatic activity increas by three- to four-fold in tissue. 
300-302 
 MMP-9 is involved in both in angiogenesis and vasculogenesis.  MMP-9 
mediated release of kit-ligand is necessary for the mobilization of endothelial progenitor 
cells from the bone marrow.285, 303-305  Locally, MMP-9 acts by degrading basement 
membrane and extracellular matrix which therefore eliminates contact inhibition that 
normally blocks endothelial cell proliferation and migration.306  Pathologic involvement 
of MMP-9 was identified in angiogenic disease of the retina.285 
MMP-9 is expressed in proliferating lesions in addition to VEGF and bFGF.214  
High molecular weight MMP was increased in urinary excretion in patients with vascular 
tumors compared to healthy controls.273  Furthermore, MMP-9 and VEGFA was 
increased in the plasma of proliferating hemangioma patients.282, 285  MMP-9 is likely 
within the mechanism pathway of hemangiomas.  It isyet to be seen if this can be used as 





Recent interest in adipogenesis stems from the ever-looming obesity epidemic and 
associated complications affecting much of the world.  Many researchers are looking at 
how to better control adipogenesis and the subsequent physiologic consequences of 
excessive fat production.  The study of adipogenesis or the differentiation of cells into fat 
is fortunately capable of being studied because fat di ferentiation in vitro is rather similar 
to adipogenesis in vivo.307, 308 Almost all work on adipogenesis has utilized either 
predetermined clonal cell lines or preadipocytes isolated from stromal-vascular fraction 
of dissociated fat pads.307  Knowledge about the differentiation requirements have been 
predominately gained through 3T3-L1 and 3T3-F442A, nonconal Swiss 3T3 cells.309, 310 
Other cell lines include TA1 311 and Ob1771.312  After treatment with a hormonal cocktail 
combination of cAMP, 3-isobutyl-1-methylxanthine, insulin, and glucocorticoids, these 
cell lines differentiation over 4 to 8 days.313 
Adipocytes are essential for energy homeostasis as well as hemostasis, blood 
pressure control, immune function, and angiogenesis.  This tissue differs from other types 
of tissue because it is dispersed throughout the body at sites of rich loose connective 
tissue as well as around the heart, kidney other int nal organs.  Fat tends to develop in 
clusters, in vivo and in vitro; however, the exact mechanism by which recruitment or 
differentiation of these clusters is unknown.314  Notably, the earliest event associated with 
the development of adipose tissue is a proliferating network of capillaries within 
subcutaneous loose tissue.   
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In vivo adipocytes originate from multipotent mesenchymal stem cells which are 
capapable of also differentiating into osteoblasts nd chondrocytes.315  As with most stem 
cell lineages, the differentiation process consists of a deterimination and terminal stage.  
The differentiation stage is the commitment of the stem cell to the adipocyte lineage and 
is accompanied by growth arrest, typically this is acquired through contact inhibition; 
however, this is not necessity for adipocyte differentiation.308, 316  Stimulated cells reenter 
the cell cycle and progress through at least two cell-cycle divisions termed mitotic clonal 
expansion.317-319  Mitosis allows for reorganization of chromatin and production of cell-
cycle machinery possibly needed to facilitate expression of adipogenic genes.320-322  
Second, the terminal differentiation of the pre-adipocyte to a mature adipocyte is when 
the cell acquires the necessary specific machinery for lipid synthesis and trafficking, 
gains insulin sensitivity and produces adipocyte-spcific proteins. 323  This includes 
triglyceride accumulation as well as glyerophophotaste dehydrogenase, fatty acid 
synthase, acetyl coA carboxylase, GLUT 4, insulin receptor aP2. 
A Complicated Transcription Cascade 
The exact details of the adipogenic differentiation transcription cascade remains 
to be completely elucidated; however, it is understood that differentiation involves a 
number of temporally regulated gene-expression events including known transcription 
factors, chromatin remodeling, feedback loops, and a umber of inhibitory factors.  The 
most well-known and studied transcription factors are the peroxisome proliferator-
activated receptors (PPARs) and the CCAAT-enhancer-binding proteins (C/EBPs).  More 
recently, the Kruppel-like factors (KLFs) have been implicated in the regulatory cascade 
of adipogenesis.  Simply put, dlk is the major inhibitory molecule of adipogenesis in 
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concert with Sox9.  As dlk and Sox9 levels decrease, C/EBPβ and δ rise transiently and 
early during differentiation, followed by the expression of PPARγ within a positive 
feedback loop with C/EBPα.  These temporally expressed factors ensure commitment and 
transcription of adipocyte-specific genes that contribu e to the necessary machinery for 
mature adipocyte function.  Certain KLF factors positively (KLF4, KLF5, KLF6, and 
KLF 15) and negatively (KLF2) regulate the aforementioned proteins.  These are the 
transcription factors that will be of focus in this manuscript in regard to the fatty-
involution of hemangiomas.  A summary of the interactions of the discussed adipogenesis 
differentiation factors can be seen in Figure 5. 
Delta-like kinase (dlk) 
Delta-like kinase (dlk also known as Pref-1) is a cellular membrane protein with 
unique characteristics.  The dlk structure consists of an extracellular six tandem 
epidermal growth factor (EGF)-like repeats.324  It also shares structural similarities to the 
Notch/Delta/Serrate family, which are involved in cell signaling and cell fate 
determination.325  However, dlk lacks a conserved binding domain as with classic Notch 
ligands.326  The extracellular domain is cleaved to generate soluable dlk.327  One of the 
enzymes found to cleave membrane bound dlk is TNFα converting enzyme (TACE, 
ADAM17).328   
 The interest in dlk in adipogenesis stems from a dramatic decrease in dlk 
expression with adipocyte differentiation; it is abundant in preadipocytes.  It is not 
detectable in mature fat cells.329, 330  It is the only known gene whose expression is 
completely down-regulated during adipocyte differentiation.  Dlk presence prevents 
differentiation, lipid accumulation and expression of adipocyte transcription factors such 
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as PPARγ, C/EBPα as well as markers FABp4/aP2.324, 331   It is a commonly used 
preadipocyte marker.5, 330, 332-338 
Although the specific target of soluable dlk is unknown, it is known that dlk 
functions through phosphorylation of ERK in the (mitogen-activated protein kinase) / 
(extracellular signal-regulated kinases) MAPK/ERK pathway.331 Dlk, through 
MAPK/ERK activation, induces expression of Sox9, a member of the Sox gene family.  
Sox9 plays an important role during emrbyogenesis, cellular differentiation, testogenesis, 
chodrnogenesis and osteoblastogenesis.324   
Sox9 inhibits adipocyte differentiation by directly binding to C/EBPβ and 
C/EBPδ gene promotors.331  Similarly to dlk expression, Sox9 expression decreases early 
in differentiation.339  This decrease in expression coincides with induction of C/EBPβ and 
C/EBPδ.  Dlk and Sox9 both promote chondrogenic induction but prevent chondrocyte 
maturation, an alternate differentiation pathway.340-343  Both, null and overexpression of 
dlk in adipose tissue results in insulin resistance and glucose intolerance.344  This 
indicates that these factors are necessary for early differentiation but not sufficient for 
proper tissue maturation.  Figure 15 illustrates the dlk mechanism of inhibition of 
adipogenesis. 
In adult tissue, dlk is only found in adipose and certain neuroendocrine tissue, 
including pericytes in the blood-brain barrier.345  Dlk, however, is found in multiple 
mouse embryonic tissues.  Likely, in addition to its role in adipogenesis, dlk also plays a 
role in determining mesenchymal stem cell fate.346  Dlk is an imprinted gene.347 
In regards to hemangiomas, dlk undergoes a 5-fold decrease on maturation of 
hemangiomas.46 This means that the very high levels of dlk expressed by proliferating 
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hemangiomas may prevent the formation of fat. Decreasing levels of dlk as the 
hemangioma matures releases this inhibition thus promoting fat formation. Given that a 
mere 2-fold increase can completely prevent the conversion of preadipocytes to 
adipocytes, it is clear that this molecule plays a critical role in the adipogenesis of 
hemangiomas. 
Peroxisome proliferator-activated receptors (PPARs) 
Peroxisome proliferator-activated receptors (PPARs) are a subgroup of the 
nuclear receptor superfamily and include PPARα, PPARβ/δ and PPARγ.  These nuclear 
receptors are ligand-dependent transcription factors that form heterodimers with retinoid 
X receptors, see Figure 16.348-352  The DNA binding domain consists of two zinc fingers 
that bind to specific peroxisome proliferator response elements (PPREs) found in 
enhancer regions.  The ligand binding domain is composed of 13 α-helices and a small 4 
stranded β sheet.320  The pocket is larger than most other nuclear receptors 353, 354 which 
may allow for a broader range of ligand interactions.  Known ligands include naturally 
occurring fatty acids and their derivatives, eicosanoids, prostaglandins as well as 
manufactured antidiabietic agents, thiazolidinediones(TZD).355  Agonist binding leads to 
conformational changes in the PPAR structure allowing for recruitment of transcriptional 
factors and thus increase in gene expression.  The TZDs, a new class of drugs which 
increase insulin sensitivity, can directly bind and activate PPARγ and stimulate adipose 
conversion.356-358 
Each receptor has a unique tissue expression profile.  PPARα is expressed in 
many metabolically active tissue including liver, kidney, heart, muscle and brown fat.359-
362  PPARβ/δ is expressed at significant levels in the brain, adipose tissue and skin.360-363 
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PPARγ exists in two isoforms created from alternative promoter usage and splicing.  
PPARγ1 is found constitutively at low levels throughout the body while PPARγ2 is 
expressed in primarily in adipose tissue but also found in fibroblasts and myoblasts.349, 
360, 362, 364 
PPARγ is critical in a variety of biological processes, including adipogenesis, 
glucose metabolism, and inflammation.365  PPARγ2 is the master regulator in adipocyte 
differentiation.  The presence of PPARγ2 is required for terminal adipocyte differentiation 
of embryonic stem cells and fibroblasts in vitro as well as in vivo differentiation.366-369  
The expression of ectopic PPARγ is sufficient to induce successful adipocyte 
differentiation in nonadipogenic mouse fibroblasts.370  Furthermore, ectopic activation by 
PPAR agonist (ETYA) leads to differentiation.370  PPARγ dominant-negative 3T3-L1 
cells were unable to differentiation into adipocytes.371, 372  To date, no factor has been 
discovered that promotes adipogenesis in the absence of PPARγ.373 
Several groups have demonstrated the critical presenc  that PPARγ plays in 
adipocyte differentiation.  Heterozygous null mice and dominant-negative PPARγ mouse 
models all exhibit reduced or absent amounts of adipose tissue.366, 374,366, 367, 372, 375, 376  
Cells in which PPARγ expression was wild or restored exhibit fully functional adipocyte 
differentiation capabilities.  Mouse models have also shown that lack of PPARγ can lead 
to insulin resistance.376, 377   
A number of genes are regulated in vivo by PPARγ.  The list includes genes 
involved in terminal differentiation of adipocytes such as adipocyte fatty acid binding 
protein (aP2), phosphoenolpyruvate (PEPCK), acyl-CoA synthetase, LPL,  CD36 (cell 
surface fatty acid), adipose-specific fatty acid binding protein (FABP4) and FATP1. 349, 
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378-381  These genes possess PPREs within their regulator regi ns.  Ligand activation of 
PPARγ is required for induction into the adipogenic pathway but is not necessary for 
PPARγ-dependent gene expression.377  Interestingly, PPARγ is necessary to maintain 
adipocytes in a differentiated state.  Mature 3T3 L1 adipocytes transfected with an 
adenovirus to dominant-negative PPARγ lead to the de-differentiation of the adipocytes 
with loss of lipid accumulation and decrease in adipocyte markers.382 
CCAAT-enhancer-binding proteins (C/EBPs) 
CCAAT-enhancer-binding proteins (C/EBPs) compile a six member (C/EBPα to 
C/EBP ζ) family of basic-leucine zipper transcription factors that promote expression of 
genes by acting at CCAAT box motifs present in several gene promoters.  These proteins 
are found predominately in hepatocytes, adipocytes, h matopoietic cells, spleen, kidney, 
and brain.  As mentioned above, C/EBPα, C/EBPβ and C/EBPδ have roles in 
adipogenesis which have been demonstrated in vivo and in vitro.  C/EBPs are important 
in adipogenesis but these factors cannot function efficiently in the absence of PPARγ.383 
C/EBPα is required for both adipogenesis and normal adipocyte differentiation.  It 
is induced later in the differentiation process andproceeds most end product genes of 
adipocytes likely by inducing the expression of PPARγ.  Ectopic expression of C/EBPα 
in 3T3-L1 cell lines promotes adipogenesis.322, 384  Furthermore, C/EBPα expression is 
necessary to maintaining PPARγ expression in mature adipocytes.385  Similar to C/EBPβ, 
ectopic expression of C/EBPα cannot initiate adipogenesis in dominant negative PPARγ 
fibroblasts.383 
The role of C/EBPα is elucidated in mice models where mice lacking C/EBPα via 
replacement of the C/EBPα locus by C/EBPβ show abnormal adipose tissue formation.   
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These mice are viable, with normal liver function; however, they have an overall 
reduction in the amount of white adipose tissue.382  In dominant negative C/EBPα mice, 
those that survive to birth died shortly afterwards due to a lack of gluconeogenesis and 
subsequent hypoglycemia; however, restoration of hepatic C/EBPα levels by liver-
specific rescue can prevent the lethality of the del tion.386, 387  Expression of exogenous 
PPARγ in C/EBPα-deficient cells showed that, C/EBPα is not required for accumulation 
of lipid and the expression of many adipocyte genes; however, it is necessary for 
acquisition of insulin sensitivity.383, 385, 388   
C/EBPβ and C/EBPδ are factors in the adipogenesis cascade but are not the most 
critical factors in the adipocyte differentiation. C/EBPβ and C/EBPδ rise early and 
transiently during adipogenesis389-391, in part by inducing expression of the adipogenic 
transcription factors C/EBPα and PPARγ.373, 392, 393  C/EBP β and δ have direct 
transcriptional effect through a binding site in PPARγ promoter.364, 385  Ectopic 
expression of C/EBPβ and C/EBPδ in 3T3-L1 preadipocytes promotes adipogenesis in 
the absence of extracellular hormones.389-391  C/EBPβ in NIH 3T3 fibroblasts, with and 
without C/EBPδ, can induce PPARγ, the key adipocyte transcription factor.  These cells 
following exposure to PPARγ ligands terminally differentiate into adipocytes.393, 394  
However, C/EBPα is not induced in the absence of a PPARγ ligand.322  C/EBPβ 
limitation in adipogenesis differentiation is shown by the incapability of adipogenesis in 
dominant negative PPARγ cells.395 
Nevertheless, C/EBPβ and C/EBPδ are necessary for proper and complete 
adipogenic function.  Tanaka and colleagues conducte  a series of experiments with 
C/EBPβ and C/EBPδ knockout mice.392  C/EBPβ knockout mice showed reduced 
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adiposity, likely do to decreased lipogenesis not adipogenesis.  Furthermore, C/EBPβ and 
C/EBPδ double-knockout had even more reduction in adipose-tis ue mass.  Murine 
embryonic fibroblasts from these double-knockout mice show deficiency in C/EBPα and 
PPARγ as well as impaired efficiency of adipocyte differentiation in response to 
adipogenic extracellular hormone stimuli.392, 396 .  However, PPARγ and C/EBPα levels 
were normal in the scant adipose tissue.  This indicated that there was another, yet less 
efficient, transcription cascade capable of regulating adipogenesis independent of the 
C/EBP mechanism.392  This was found to be ADD1/SREBP1.  Furthermore, it was found 
that C/EBPβ cannot induce expression of C/EBPα in the absence of PPARγ because 
PPARγ is required to release histone deacytelase-1(HDAC1) from the C/EBPα 
promoter.395 
Krüppel-like Factors (KLFs) 
The Krüppel-like factor family is an important family homologous to the 
Drosophila melanogaster embryonic segmentation gene product, Krüppel.397, 398  The 
characteristic and highly conserved three Kruppel-lik  Cys2/His2 zinc-fingers bind at the 
C terminus to the CACCC/GC/GT-box,399, 400 found in the regulatory regions of genes, 
controlling various biological processes.  Similarities in structure create overlap in 
transcriptional targets.  However, the N terminus is highly variable and is also involved in 
gene activation, gene repression, or both, as well as in protein-protein interactions.66 
KLF tissue expression is variable while some are expr ssed ubiquitously (KLF6, 
KLF10, KLF11) others are tissue specific (KLF1, eryth oid; KLF2, lung; KLF4 and 
KLF5, intestines).397  KLFs regulate a broad spectrum of processes including 
proliferation, apoptosis, differentiation, development and cell cycle progression401, 402 as 
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well as specifics involved in hematopoiesis,403, 404 cardiac remodeling,405 and vascular 
biology.406  Alterations in their function have been associated with the pathobiology of 
numerous human disease including cardiovascular disease, metabolic disorders, and 
cancer.66, 407-409 
Reviewed in detail in McConnell and Yang’s 2010 review are the mechanisms of 
action of KLFs.66  In summary, KLF actions vary by a number of biochemical 
modulations leading to chromatin modifiers, cofactors, and transcriptional machinery.  
These modulations vary by group and include: histone aceytyltransferases, CtBP via 
histone deactylases (HDACs), and Sin3A via HDAC1 and HDAC2.  Posttranslational 
modifications needed for KLFs to bind to promoter/enhancer sequences include: 
acetylation, phosphorylation, ubiquitiation, and sumolyation.  Table 17 provides an 
excellent general overview of the function and regulations of all KLFs. 
In relation to adipogenesis, the  functional  CACCC binding  sites  are  found  in  
the  control  region  of  key adipogenic  factors,  such  as  C/EBPα  and  PPARγ.  
Subsequently, a handful of KLFs have been identified as critical regulatory molecules in 
the transcriptional cascade controlling adipocyte diff rentiation.407, 409-412  These include: 
KLF2, KLF3, KLF4, KLF5, KLF6, KLF7, KLF11, KLF15.  From McConnel and Yang, 
Figure 5 demonstrates the regulatory effects that KLFs have on during adipogenesis.   
KLF2,  KLF3, and KLF7 inhibit adipocyte differentiaon in part through 
inhibition of PPARγ and C/EBPα expression.413-416 Further more, KLF2 promotes a 
quiescent phenotype by blocking expression of the growth promoting c-myc.417  KLF11 
inhibits adipogenesis more indirectly though cholesterol metabolism pathways.418 
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KLF4 and KLF5 promote adipogenesis early in differentiation via transcription 
factors C/EBPβ, C/EBPδ and PPARγ.410, 419  Mice lacking KLF4 die shortly after birth 
secondary to defects in skin development as the fat layer is disrupted and the barrier 
function of the skin is inadequate.420  KLF6 is proadipogenic as it represses the main 
inhibitor of adipogenesis, dlk.421  Finally, KLF15 promotes adipocyte differentiation a d 
is suspected to be activated by early transcription factors, C/EBPβ and C/EBPδ, 
subsequently inducing PPARγ, C/EBPα and adipocyte differentiation.422, 423 
Also of interest is that KLFs play a regulatory role in cell progression.  KLFs can 
reprogram somatic cells into inducible pluripotent stem cells and maintain embryonic 
stem cells.424-426 Specifically, KLF2, KLF4, and KLF5 work in concert with Nanog to 
maintain the self-renewal of the embryonic stem cell.424  More so, KLF4 and KLF5 were 
identified as upstream factors in the transcriptional regulatory circuit for somatic cell 





Table 1: List of qRT-PCR probes  
Purchased from Applied Biosystems (Foster City, CA) as Gene Expression Assays (20x), 










CEBPB  NM_005194  Hs00270923_s1* Hs.517106  
CEBPD  NM_005195  Hs00270931_s1* Hs.440829  
DLK1  NM_003836  Hs02574620_s1* Hs.533717  
KLF2  NM_016270  Hs00360439_g1* Hs.715677  
KLF4  NM_004235  Hs00358836_m1* Hs.376206  
KLF5 NM_001730 Hs00156145_m1* Hs.508234 
KLF6 NM_001300 Hs00810569_m1* Hs.4055 
KLF15  NM_014079  Hs00362736_m1* Hs.272215  
PPARG  NM_015869  Hs01115513_m1* Hs.162646  
RXRA  NM_002957  Hs01067640_m1* Hs.590886  
SREBF1  NM_004176  Hs01088691_m1* Hs.592123  
SOX9 NM_000346 Hs00165814_m1* Hs.647409 
NGFR NM_002507.2 Hs00609976_m1* Hs.415768 
POU5F1 NM_002701 Hs03005111_g1 Hs.249184 
SOX2 NM_003106.2 Hs01053049_s1* Hs.518438 
NANOG NM_024865.2 Hs02387400_g1* Hs.635882   




Table 2: List of antibodies for staining and IHC-P and IF results 
 
Listed are the antibodies utilized from AbCam, (Cabridge, MA), the manufacturer 
details and summary of staining for both immunohistochemistry (IHC-P) and 
immunofluorescence (IF), legend below table. 
Details Data 
Protein AbCam Number 
IgG Clonal IHC-P IF 
Diagnostic Marker for Hemangioma      
GLUT1 ab40084 mouse mono + + 
Stem Cell / Neural Crest         
Nestin ab22035 mouse mono + + 
NG2 ab78284 mouse mono Ø ± 
NGFR ab78387 mouse mono - - 
Sox2 ab15830 rabbit poly Ø + 
Sox10 ab25978 rabbit poly Ø - 
Pericyte Marker         
Calponin ab46794 rabbit mono Ø + 
DLK ab21682 rabbit poly + + 
SMA ab7817 mouse mono + + 
Desmin ab15200 rabbit poly - Ø 
PDGFR-β ab55571 mouse mono - - 
Endothelial Cell Marker         
CD31 ab28364 rabbit poly Ø + 
      
+ positive staining     
± weak positive staining     
- negative staining     



















 Table 4: Descriptive statistics for qRT-PCR relative expression 
 
Descriptive statistics for each of the hemangioma ph ses for each of the mRNA 
probes examined using qRT-PCR ∆∆Ct relative expression compared to HDMEC. 
    N Mean Std. Deviation Std. Error 
Proliferative 4 1463.00 1467.16 733.58 
Early Quiescent 3 10.73 12.48 7.21 
Late Quiescent 3 657.30 599.30 346.01 
Involuted 2 425.82 534.52 377.96 
SOX2 
Total 12 725.64 1016.41 293.41 
Proliferative 3 2477.58 3543.04 2045.57 
Early Quiescent 3 896.89 730.07 421.50 
Late Quiescent 3 1672.32 1816.25 1048.61 
Involuted 2 19534.35 3137.51 2218.56 
SOX9 
Total 11 4928.10 7535.69 2272.10 
Proliferative 4 2672.87 4400.52 2200.26 
Early Quiescent 3 942.07 1444.37 833.91 
Late Quiescent 3 1930.14 2845.67 1642.95 
Involuted 2 365.96 405.78 286.93 
Pauf5 
Total 12 1670.00 2825.91 815.77 
Proliferative 4 2340.02 3378.05 1689.03 
Early Quiescent 3 862.76 1336.71 771.75 
Late Quiescent 3 288.40 463.26 267.46 
Involuted 2 161.70 140.50 99.35 
Nanog 
Total 12 1094.75 2095.72 604.98 
Proliferative 4 17985.92 18484.49 9242.25 
Early Quiescent 3 18906.35 18513.50 10688.77 
Late Quiescent 3 4033.77 6170.50 3562.54 
Involuted 2 478.11 556.18 393.28 
NGFR 










Continued Table 4: Descriptive statistics for qRT-PCR relative expression  
    N Mean Std. Deviation Std. Error 
Proliferative 5 4.90E+04 5.32E+04 2.38E+04 
Early Quiescent 2 1.34E+04 5.29E+03 3.74E+03 
Late Quiescent 3 2.64E+04 1.34E+04 7.76E+03 
Involuted 3 9.93E+04 1.19E+05 6.85E+04 
DLK 
Total 13 4.99E+04 6.56E+04 1.82E+04 
Proliferative 4 1.30 1.32 .66 
Early Quiescent 3 1.58 2.31 1.33 
Late Quiescent 4 1.33 1.05 .53 
Involuted 3 .06 .10 .06 
PPARγ 
Total 14 1.10 1.35 .36 
Proliferative 4 298.76 159.50 79.75 
Early Quiescent 3 36.63 6.66 3.85 
Late Quiescent 3 1034.70 507.95 293.27 
Involuted 3 1197.37 1145.62 661.43 
C/EBPα 
Total 13 615.47 716.87 198.82 
Proliferative 3 .28 .07 .04 
Early Quiescent 3 .01 .01 .00 
Late Quiescent 3 .22 .13 .08 
Involuted 2 .27 .15 .11 
C/EBPβ 
Total 11 .19 .14 .04 
Proliferative 3 .51 .33 .19 
Early Quiescent 3 1.74 1.51 .87 
Late Quiescent 2 .64 .13 .09 
Involuted 1 .35 . . 
C/EBPδ 
Total 9 .93 .99 .33 
Proliferative 5 .43 .32 .14 
Early Quiescent 3 .36 .22 .13 
Late Quiescent 4 .89 .44 .22 
Involuted 2 .43 .11 .08 
RXR 
Total 14 .55 .37 .10 
Proliferative 5 .33 .32 .14 
Early Quiescent 3 .16 .10 .06 
Late Quiescent 4 .47 .21 .11 
Involuted 2 .15 .11 .08 
SREBF 
Total 14 .31 .25 .07 
      





Continued Table 4: Descriptive statistics for qRT-PCR relative expression  
    N Mean Std. Deviation Std. Error 
Proliferative 4 13.89 25.28 12.64 
Early Quiescent 3 19.84 16.13 9.31 
Late Quiescent 3 771.20 662.94 382.75 
Involuted 3 176.45 68.26 39.41 
KLF2 
Total 13 227.54 418.06 115.95 
Proliferative 3 43.51 67.18 38.79 
Early Quiescent 3 6.99 6.18 3.57 
Late Quiescent 3 310.81 260.24 150.25 
Involuted 2 69.47 12.00 8.48 
KLF4 
Total 11 111.17 177.21 53.43 
Proliferative 4 13.73 10.57 5.28 
Early Quiescent 3 5.54 7.10 4.10 
Late Quiescent 3 78.89 118.58 68.46 
Involuted 3 1417.03 2300.04 1327.93 
KLF5 
Total 13 350.71 1120.02 310.64 
Proliferative 3 8.53 7.10 4.10 
Early Quiescent 3 47.55 15.64 9.03 
Late Quiescent 3 299.94 441.95 255.16 
Involuted 2 21.85 2.43 1.72 
KLF6 
Total 11 101.07 235.95 71.14 
Proliferative 3 4.23 6.02 3.47 
Early Quiescent 3 8.08 11.23 6.48 
Late Quiescent 3 48.79 79.19 45.72 
Involuted 3 28.92 15.03 8.68 
KLF15 











Table 5: One-way ANOVA 
ANOVA results for comparison of multiple hemangioma phases, significant 
differences, p<0.05 indicated in bold 
  Sum of Squares df Mean Square F Sig. 
Between Groups 3901855.44 3 1300618.48 1.394 .313 
Within Groups 7462056.77 8 932757.10     
SOX2 
Total 11363912.22 11       
Between Groups 525252234.23 3 175084078.08 28.760 .000 
Within Groups 42613757.04 7 6087679.58     
SOX9 
Total 567865991.27 10       
Between Groups 9216725.36 3 3072241.79 .313 .816 
Within Groups 78626505.17 8 9828313.15     
Pauf5 
Total 87843230.52 11       
Between Groups 10056018.47 3 3352006.16 .701 .577 
Within Groups 38256256.62 8 4782032.08     
Nanog 
Total 48312275.08 11       
Between Groups 741875196.23 3 247291732.08 1.107 .401 
Within Groups 1786987966.56 8 223373495.82     
NGFR 
Total 2528863162.80 11       
Between Groups 1.17E+10 3 3.88E+09 .875 .489 
Within Groups 3.99E+10 9 4.44E+09     
DLK 
Total 5.16E+10 12       
Between Groups 4.32 3 1.44 .749 .547 
Within Groups 19.23 10 1.92     
PPARγ 
Total 23.55 13       
Between Groups 2949495.03 3 983165.01 2.750 .105 
Within Groups 3217340.86 9 357482.32     
C/EBPα 
Total 6166835.89 12       
Between Groups .14 3 .05 4.776 .041 
Within Groups .07 7 .01     
C/EBPβ 
Total .21 10       
Between Groups 3.04 3 1.01 1.051 .447 
Within Groups 4.81 5 .96     
C/EBPδ 
Total 7.85 8       
Between Groups .66 3 .22 2.016 .176 
Within Groups 1.09 10 .11     
RXR 
Total 1.76 13       
Between Groups .23 3 .08 1.366 .309 
Within Groups .56 10 .06     
SREBF 
Total .79 13       
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Continued Table 5: One-way ANOVA 
  Sum of Squares df Mean Square F Sig. 
Between Groups 1206527.54 3 402175.85 4.064 .044 
Within Groups 890724.36 9 98969.37     
KLF2 
Total 2097251.90 12       
Between Groups 169343.82 3 56447.94 2.731 .124 
Within Groups 144695.89 7 20670.84     
KLF4 
Total 314039.71 10       
Between Groups 4444392.94 3 1481464.31 1.257 .346 
Within Groups 10608962.37 9 1178773.60     
KLF5 
Total 15053355.31 12       
Between Groups 165480.43 3 55160.14 .987 .452 
Within Groups 391229.40 7 55889.91     
KLF6 
Total 556709.83 10       
Between Groups 3823.64 3 1274.55 .766 .545 
Within Groups 13318.01 8 1664.75     
KLF15 

















Table 6: Tukey post hoc analysis 
Post hoc analysis to determine source of significant differences identified with one-way 
ANOVA, significant values p<0.05 in bold. 
Dependent 





Early  Quiescent 1580.68 2014.56 .859 
Late  Quiescent 805.26 2014.56 .977 
Proliferative 
Involuted -17056.77 2252.35 .001 
Proliferative -1580.68 2014.56 .859 
Late  Quiescent -775.43 2014.56 .979 
Early  Quiescent 
Involuted -18637.45 2252.35 .000 
Proliferative -805.26 2014.56 .977 
Early  Quiescent 775.43 2014.56 .979 
Late  Quiescent 
Involuted -17862.03 2252.35 .000 
Proliferative 17056.76873* 2252.35 .001 
Early  Quiescent 18637.45247* 2252.35 .000 
SOX9 
Involuted 
Late  Quiescent 17862.02691* 2252.35 .000 
Early  Quiescent .27110* .08 .047 
Late  Quiescent .06 .08 .869 
Proliferative 
Involuted .01 .09 1.000 
Proliferative -.27110* .08 .047 
Late  Quiescent -.21 .08 .126 
Early  Quiescent 
Involuted -.27 .09 .080 
Proliferative -.06 .08 .869 
Early  Quiescent .21 .08 .126 
Late  Quiescent 
Involuted -.06 .09 .922 
Proliferative -.01 .09 1.000 
Early  Quiescent .27 .09 .080 
C/EBPβ 
Involuted 
Late  Quiescent .06 .09 .922 
Early  Quiescent -5.95 240.28 1.000 
Late  Quiescent -757.30873* 240.28 .048 
Proliferative 
Involuted -162.56 240.28 .903 
Proliferative 5.95 240.28 1.000 
Late  Quiescent -751.36 256.86 .067 
Early  Quiescent 
Involuted -156.61 256.86 .926 
Proliferative 757.30873* 240.28 .048 
Early  Quiescent 751.36 256.86 .067 
Late  Quiescent 
Involuted 594.75 256.86 .165 
Proliferative 162.56 240.28 .903 
Early  Quiescent 156.61 256.86 .926 
KLF2 
Involuted 





Figure 15:  Dlk mechanism of action 
 
Dlk (shown as Pref-1 in this image) inhibits 
adipogenesis.  Here the membrane bound 
dlk is cleaved by TACE to form soluble dlk.  
The target of soluble dlk remains unknown.  
Through activating the MEK/ERK pathway 
Sox9 expression increases.  Sox9 binds the 
promoters and inhibits the expression of 
C/EBPβ and C/EBPδ.  Figure from Sul’s 






Figure 16:  PPARγ Binding Motif and Cofactors  
Illustration of necessary binding 
for terminal genes to form mature 
adipocyte. Image from Choi’s 
review of Artepellin and PPARγ 429 
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Figure 17:  Review of Krϋppel-like Factor Functions 
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